DE69031763T2 - Steigerungsverfahren der transmembranförderung von exogenen molekülen - Google Patents

Steigerungsverfahren der transmembranförderung von exogenen molekülen

Info

Publication number
DE69031763T2
DE69031763T2 DE69031763T DE69031763T DE69031763T2 DE 69031763 T2 DE69031763 T2 DE 69031763T2 DE 69031763 T DE69031763 T DE 69031763T DE 69031763 T DE69031763 T DE 69031763T DE 69031763 T2 DE69031763 T2 DE 69031763T2
Authority
DE
Germany
Prior art keywords
exogenic
transmembrane
conveyor
molecules
folate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69031763T
Other languages
English (en)
Other versions
DE69031763D1 (de
Inventor
Philip Low
Mark Horn
Peter Heinstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Application granted granted Critical
Publication of DE69031763D1 publication Critical patent/DE69031763D1/de
Publication of DE69031763T2 publication Critical patent/DE69031763T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
    • C12N15/8206—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation by physical or chemical, i.e. non-biological, means, e.g. electroporation, PEG mediated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
DE69031763T 1989-04-03 1990-04-02 Steigerungsverfahren der transmembranförderung von exogenen molekülen Expired - Fee Related DE69031763T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33181689A 1989-04-03 1989-04-03
US07/498,762 US5108921A (en) 1989-04-03 1990-03-28 Method for enhanced transmembrane transport of exogenous molecules
PCT/US1990/001739 WO1990012096A1 (en) 1989-04-03 1990-04-02 Method for enhancing transmembrane transport of exogenous molecules

Publications (2)

Publication Number Publication Date
DE69031763D1 DE69031763D1 (de) 1998-01-08
DE69031763T2 true DE69031763T2 (de) 1998-06-25

Family

ID=26987937

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69031763T Expired - Fee Related DE69031763T2 (de) 1989-04-03 1990-04-02 Steigerungsverfahren der transmembranförderung von exogenen molekülen

Country Status (13)

Country Link
US (4) US5108921A (de)
EP (1) EP0466816B1 (de)
JP (1) JP3232347B2 (de)
AT (1) ATE160583T1 (de)
AU (1) AU5437590A (de)
CA (2) CA2013582C (de)
DE (1) DE69031763T2 (de)
DK (1) DK0466816T3 (de)
ES (1) ES2113346T3 (de)
IE (1) IE81171B1 (de)
IL (1) IL93983A (de)
PT (1) PT93646A (de)
WO (1) WO1990012096A1 (de)

Families Citing this family (865)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550111A (en) * 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
US5643889A (en) * 1984-07-11 1997-07-01 Temple University-Of The Commonwealth System Of Pennsylvania Cholesterol conjugates of 2'5'-oligoadenylate derivatives and antiviral uses thereof
US5688488A (en) * 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US20040142899A1 (en) * 1990-01-11 2004-07-22 Isis Pharmaceuticals, Inc. Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
US6153737A (en) * 1990-01-11 2000-11-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US6753423B1 (en) 1990-01-11 2004-06-22 Isis Pharmaceuticals, Inc. Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
US6114513A (en) 1990-01-11 2000-09-05 Isis Pharmaceuticals, Inc. Thiol-derivatized oligonucleotides
US7037646B1 (en) 1990-01-11 2006-05-02 Isis Pharmaceuticals, Inc. Amine-derivatized nucleosides and oligonucleosides
US6395492B1 (en) * 1990-01-11 2002-05-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
ATE195656T1 (de) * 1991-06-05 2000-09-15 Univ Connecticut Zielgerichtete freisetzung von genen, die sekretorische proteine kodieren
US6287792B1 (en) * 1991-06-17 2001-09-11 The Regents Of The University Of California Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
US5981273A (en) * 1991-09-30 1999-11-09 Boehringer Ingelheim Int'l. Gmbh Composition comprising an endosomolytic agent for introducing nucleic acid complexes into higher eucaryotic cells
US5254342A (en) * 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US6335434B1 (en) 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
US6831166B2 (en) 1992-10-23 2004-12-14 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
AU671450B2 (en) * 1992-03-20 1996-08-29 Baylor College Of Medicine A DNA transporter system and method of use
US6033884A (en) * 1992-03-20 2000-03-07 Baylor College Of Medicine Nucleic acid transporter systems and methods of use
WO1994004194A1 (en) * 1992-08-14 1994-03-03 Massachusetts Institute Of Technology Nucleic acid recognition and transport
US20020173474A1 (en) * 1993-02-12 2002-11-21 President And Fellows Of Harvard College Methods & materials involving dimerization-mediated regulation of biological events
US5993860A (en) * 1993-06-17 1999-11-30 Venture Lending NSADI delivery employing a powdered hydrocolloid gum obtainable from higher plants
US6653458B1 (en) 1993-09-03 2003-11-25 Isis Pharmaceuticals, Inc. Modified oligonucleotides
CA2170869C (en) 1993-09-03 1999-09-14 Phillip Dan Cook Amine-derivatized nucleosides and oligonucleosides
US5635385A (en) * 1993-09-15 1997-06-03 Temple University-Of The Commonwealth System Of Higher Education Multi-unit ribozyme inhibition of oncogene gene expression
US6077835A (en) * 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
US5972901A (en) * 1994-03-23 1999-10-26 Case Western Reserve University Serpin enzyme complex receptor--mediated gene transfer
US5844107A (en) * 1994-03-23 1998-12-01 Case Western Reserve University Compacted nucleic acids and their delivery to cells
WO1995025809A1 (en) * 1994-03-23 1995-09-28 Ohio University Compacted nucleic acids and their delivery to cells
EP0758196A4 (de) * 1994-05-05 1999-05-06 Univ Pennsylvania Zusammensetzungen und verfahren zur tumorbehandlung
US5670347A (en) 1994-05-11 1997-09-23 Amba Biosciences Llc Peptide-mediated gene transfer
US5716594A (en) * 1994-06-06 1998-02-10 The Jmde Trust Biotin compounds for targetting tumors and sites of infection
AU700864B2 (en) * 1994-06-06 1999-01-14 David R. Elmaleh Biotin compounds for targetting tumors and sites of infection
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
AU8122094A (en) 1994-10-19 1996-05-15 Human Genome Sciences, Inc. Human hypoxanthine-(guanine) phosphoribosyl transferase-2
IL114615A0 (en) 1995-07-16 1995-11-27 Yeda Res & Dev Modulators of the function of fas receptors and other proteins
CA2212682A1 (en) 1995-02-10 1996-08-15 Worcester Foundation For Experimental Biology, Inc. Delivery of exogenous compounds
US5846743A (en) * 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
US5674748A (en) 1995-03-14 1997-10-07 Thomas Jefferson University Human cyclin-dependent kinase-like proteins and methods of using the same
US5547668A (en) * 1995-05-05 1996-08-20 The Board Of Trustees Of The University Of Illinois Conjugates of folate anti-effector cell antibodies
US5672500A (en) 1995-05-18 1997-09-30 Thomas Jefferson University Mch2, an apoptotic cysteine protease, and compositions for making and methods of using the same
US5817789A (en) * 1995-06-06 1998-10-06 Transkaryotic Therapies, Inc. Chimeric proteins for use in transport of a selected substance into cells
US6420549B1 (en) 1995-06-06 2002-07-16 Isis Pharmaceuticals, Inc. Oligonucleotide analogs having modified dimers
US5912160A (en) * 1995-08-22 1999-06-15 Thomas Jefferson University Gab1, Grb2 binding protein, and compositions for making and methods of using the same
US20030119724A1 (en) * 1995-11-22 2003-06-26 Ts`O Paul O.P. Ligands to enhance cellular uptake of biomolecules
CA2279669A1 (en) * 1995-12-15 1997-06-16 Enzo Therapeutics, Inc. Property effecting and/or property exhibiting constructs for the expression of non-native nucleic acid processing components for therapeutic and diagnostic uses
US20040014709A1 (en) * 1996-01-08 2004-01-22 Canji, Inc. Methods and compositions for interferon therapy
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US20050025742A1 (en) * 1996-01-08 2005-02-03 Canji, Inc. Methods and compositions for interferon therapy
US6344436B1 (en) 1996-01-08 2002-02-05 Baylor College Of Medicine Lipophilic peptides for macromolecule delivery
US6392069B2 (en) 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US7002027B1 (en) 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US6180767B1 (en) 1996-01-11 2001-01-30 Thomas Jefferson University Peptide nucleic acid conjugates
US6060587A (en) 1996-01-29 2000-05-09 The Trustees Of The University Of Pennsylvania Cellular receptor for HIV-1 VPR essential for G2/M phase transition of the cell cycle
US5783566A (en) * 1996-05-10 1998-07-21 California Institute Of Technology Method for increasing or decreasing transfection efficiency
CA2174803C (en) * 1996-04-23 2000-07-11 Jonathan P. Wong Use of liposome encapsulated ciprofloxacin as an immunotherapeutic drug
US6261787B1 (en) 1996-06-03 2001-07-17 Case Western Reserve University Bifunctional molecules for delivery of therapeutics
US6072041A (en) * 1996-06-03 2000-06-06 Case Western Reserve University Fusion proteins for protein delivery
US6310052B1 (en) 1996-06-04 2001-10-30 Queen's University At Kingston Nitrate esters and their use for neurological conditions
JPH09324000A (ja) * 1996-06-05 1997-12-16 Suntory Ltd インターロイキン−２受容体を特異的に認識する因子とリボヌクレアーゼとの接合体
US20040171031A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US20050119470A1 (en) * 1996-06-06 2005-06-02 Muthiah Manoharan Conjugated oligomeric compounds and their use in gene modulation
US20070275921A1 (en) * 1996-06-06 2007-11-29 Isis Pharmaceuticals, Inc. Oligomeric Compounds That Facilitate Risc Loading
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US20050042647A1 (en) * 1996-06-06 2005-02-24 Baker Brenda F. Phosphorous-linked oligomeric compounds and their use in gene modulation
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
WO1998020887A1 (en) * 1996-11-14 1998-05-22 Brigham And Women's Hospital, Inc. Polyphosphoinositide binding peptides for intracellular drug delivery
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
US6797276B1 (en) * 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US6942963B1 (en) 1997-01-10 2005-09-13 Massachusetts Institute Of Technology Methods for identifying treatments for neurotoxicity in Alzheimer's disease caused by β-amyloid peptides
CA2277519A1 (en) 1997-01-10 1998-07-16 Massachusetts Institute Of Technology Treatments for neurotoxicity in alzheimer's disease by .beta.-amyloid peptides
DK0994728T3 (da) 1997-04-09 2008-12-01 Intellect Neurosciences Inc Rekombinante antistoffer, som er specifikke for beta-amyloide ender, DNA, der koder derfor, samt fremgangsmåder til anvendelse heraf
US6716625B1 (en) 1997-04-16 2004-04-06 Claude Selitrennikoff Histidine kinases of Aspergillus and other fungal species, related compositions, and methods of use
US6037461A (en) * 1997-05-20 2000-03-14 Thomas Jefferson University FADD-like anti-apoptotic molecules, methods of using the same, and compositions for and methods of making the same
EP1012331B1 (de) 1997-07-01 2006-03-29 Isis Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
US7151172B1 (en) 1997-09-18 2006-12-19 The Trustees Of The University Of Pennsylvania Attenuated vif DNA immunization cassettes for genetic vaccines
US6417160B1 (en) 1997-10-14 2002-07-09 Nadine A. Tatton Methods for increasing schwann cell survival
GB9721901D0 (en) 1997-10-16 1997-12-17 Univ Manchester Particles
US20040258703A1 (en) * 1997-11-14 2004-12-23 The Government Of The Us, As Represented By The Secretary Of The Army Skin-active adjuvants for transcutaneous immunization
AU2970299A (en) * 1998-02-10 1999-08-23 Ohio State University Research Foundation, The Compositions and methods for polynucleotide delivery
US20040002079A1 (en) * 1998-02-11 2004-01-01 Gunn Robert B. Sodium-phosphate cotransporter in lithium therapy for the treatment of mental illness
US20020137786A1 (en) * 1998-02-12 2002-09-26 William G. Tatton Deprenyl compounds to treat viral infections and reduce tissue damage associated therewith
US20090011984A1 (en) * 1998-02-23 2009-01-08 Seppo Yla-Herttuala Biotin-binding receptor molecules
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US6329356B1 (en) * 1998-04-10 2001-12-11 Neurochem, Inc. Phosphono-carboxylate compounds for treating amyloidosis
US6093382A (en) * 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
JP2003524586A (ja) * 1998-05-21 2003-08-19 アイシス・ファーマシューティカルス・インコーポレーテッド オリゴヌクレオチドの非−非経口投与のための組成物と方法
US6300319B1 (en) 1998-06-16 2001-10-09 Isis Pharmaceuticals, Inc. Targeted oligonucleotide conjugates
US20030219427A1 (en) * 1998-08-18 2003-11-27 Allen Hamish J. TPL-2/COT kinase and methods of use
US6077709A (en) 1998-09-29 2000-06-20 Isis Pharmaceuticals Inc. Antisense modulation of Survivin expression
US6448078B1 (en) 1998-10-09 2002-09-10 The Trustees Of The University Of Pennsylvania Cellular receptor for HIV-1 Vpr essential for G2/M phase transition of the cell cycle
US20050063950A1 (en) * 1998-11-19 2005-03-24 Georgetown University Systemic viral/ligand gene delivery system and gene therapy
AU1628800A (en) 1998-11-19 2000-06-05 Georgetown University Systemic viral/ligand gene delivery system and gene therapy
ATE385778T1 (de) * 1998-12-18 2008-03-15 Hadasit Med Res Service Verfahren zur verabreichung von einer verbindung an mehrfachresistente zellen
US6974698B1 (en) 1999-01-15 2005-12-13 The United States Of America As Represented By The Department Of Health And Human Services Methods for delivering biologically active molecules into cells
WO2000052210A2 (en) * 1999-03-01 2000-09-08 Variagenics, Inc. Methods for targeting rna molecules
US6713280B1 (en) 1999-04-07 2004-03-30 Thomas Jefferson University Enhancement of peptide cellular uptake
EP2368575B1 (de) * 1999-04-08 2014-10-01 Intercell USA, Inc. Trockenformulierung für transkutane immunisierung
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
GB9908195D0 (en) 1999-04-09 1999-06-02 Microbiological Res Authority Treatment of intracellular infection
EP1276483B1 (de) * 1999-04-28 2009-09-02 BELLUS Health (International) Limited Zusammensetzungen und verfahren zur behandlung von amyloidosis mit sulphonatderivaten
US6609113B1 (en) * 1999-05-03 2003-08-19 The Chase Manhattan Bank Method and system for processing internet payments using the electronic funds transfer network
AUPQ014699A0 (en) * 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using nanoparticles
US6562836B1 (en) * 1999-05-24 2003-05-13 Queen's University Of Kingston Methods and compounds for inhibiting amyloid deposits
US6656730B1 (en) * 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
JP2003505518A (ja) * 1999-07-29 2003-02-12 ケース ウェスタン リザーブ ユニバーシティ セルピン酵素複合体受容体を介する増強された送達
ATE354655T1 (de) 1999-08-24 2007-03-15 Medarex Inc Humane antikörper gegen ctla-4 und deren verwendungen
AU7082400A (en) * 1999-08-26 2001-03-19 Sydney Brenner Drug conjugates and methods of designing the same
US6692724B1 (en) 1999-10-25 2004-02-17 Board Of Regents, The University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US7067111B1 (en) 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
CA2391534A1 (en) * 1999-11-15 2001-05-25 Drug Innovation & Design, Inc. Selective cellular targeting: multifunctional delivery vehicles
US8571975B1 (en) 1999-11-24 2013-10-29 Jpmorgan Chase Bank, N.A. System and method for sending money via E-mail over the internet
WO2001041784A1 (en) * 1999-12-09 2001-06-14 The Regents Of The University Of California Methods and compositions for use in the treatment of filovirus mediated disease conditions
US6933108B2 (en) 1999-12-09 2005-08-23 The Regents Of The University Of California Methods and compositions for use in the treatment of filovirus mediated disease conditions
US6261840B1 (en) 2000-01-18 2001-07-17 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
US20020055479A1 (en) 2000-01-18 2002-05-09 Cowsert Lex M. Antisense modulation of PTP1B expression
GB0002814D0 (en) 2000-02-09 2000-03-29 Univ York Nucleic acids and their uses
AU3811101A (en) * 2000-02-11 2001-08-20 Lawrence Blatt Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
US7491805B2 (en) * 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US8202979B2 (en) * 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
WO2005041859A2 (en) * 2003-04-30 2005-05-12 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery.
US7833992B2 (en) * 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US20030176385A1 (en) * 2000-02-15 2003-09-18 Jingfang Ju Antisense modulation of protein expression
WO2001074382A1 (en) * 2000-03-31 2001-10-11 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
CN1095472C (zh) 2000-04-17 2002-12-04 上海复康医药科技发展有限公司 叶酸－多聚糖复合物，其制备方法和以该复合物为活性成分的药物组合物
EP1282646B1 (de) 2000-05-08 2012-04-11 Celldex Research Corporation Humane monoklonale antikörper gegen dendritische zellen
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
US6680172B1 (en) 2000-05-16 2004-01-20 Regents Of The University Of Michigan Treatments and markers for cancers of the central nervous system
CN1292798C (zh) * 2000-06-02 2007-01-03 德克萨斯州立大学董事会 乙二半胱氨酸(ec)－药物缀合物
US20080032942A1 (en) * 2000-08-30 2008-02-07 Mcswiggen James RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
US20050209179A1 (en) * 2000-08-30 2005-09-22 Sirna Therapeutics, Inc. RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
WO2002036073A2 (en) * 2000-11-02 2002-05-10 Smithkline Beecham Corporation Receptor antagonist-lipid conjugates and delivery vehicles containing same
US7067550B2 (en) * 2000-11-03 2006-06-27 Massachusetts Institute Of Technology Treatments for neurotoxicity in Alzheimer's Disease
EP1341548A4 (de) * 2000-11-03 2006-06-14 Massachusetts Inst Technology VERFAHREN ZUR IDENTIFIZIERUNG VON BEHANDLUNGEN GEGEN NEUROTOXIZITÄT BEI ALZHEIMER-KRANKHEIT, DIE DURCH $g(b)-AMYLOIDPEPTIDE HERVORGERUFEN WIRD
EP1355672A2 (de) 2000-12-01 2003-10-29 Cell Works Inc. "konjugate von glykosylierten/galaktosylierten peptiden, bifunktionellen linkern und nukleotid?monomeren/polymeren, damit zusammenhängende zusammensetzungen, sowie verfahren zu ihrer verwendung"
CA2437899C (en) * 2001-02-13 2012-05-15 Gregory M. Glenn Vaccine for transcutaneous immunization against etec-caused traveler's diarrhea
DE60231868D1 (de) * 2001-04-24 2009-05-20 Purdue Research Foundation Folat-mimetika und deren folatrezeptorbindende konjugate
CA2444383A1 (en) * 2001-04-26 2002-11-07 Board Of Regents, The University Of Texas System Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use
WO2002087424A2 (en) 2001-05-02 2002-11-07 Purdue Research Foundation Treatment and diagnosis of macrophage mediated disease
US20050196767A1 (en) * 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
US20050282188A1 (en) * 2001-05-18 2005-12-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20060019913A1 (en) * 2001-05-18 2006-01-26 Sirna Therapeutics, Inc. RNA interference mediated inhibtion of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
US20050222066A1 (en) * 2001-05-18 2005-10-06 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050159380A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of angiopoietin gene expression using short interfering nucleic acid (siNA)
US20050176664A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering nucleic acid (siNA)
US20040198682A1 (en) * 2001-11-30 2004-10-07 Mcswiggen James RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
US20040209831A1 (en) * 2002-02-20 2004-10-21 Mcswiggen James RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA)
US20050209180A1 (en) * 2001-05-18 2005-09-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
US20050182009A1 (en) * 2001-05-18 2005-08-18 Sirna Therapeutics, Inc. RNA interference mediated inhibition of NF-Kappa B / REL-A gene expression using short interfering nucleic acid (siNA)
US20050136436A1 (en) * 2001-05-18 2005-06-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of G72 and D-amino acid oxidase (DAAO) gene expression using short interfering nucleic acid (siNA)
US20050227935A1 (en) * 2001-05-18 2005-10-13 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA)
US20060241075A1 (en) * 2001-05-18 2006-10-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (siNA)
US20050287128A1 (en) * 2001-05-18 2005-12-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
US20050187174A1 (en) * 2001-05-18 2005-08-25 Sirna Therapeutics, Inc. RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
US20060142225A1 (en) * 2001-05-18 2006-06-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of cyclin dependent kinase-2 (CDK2) gene expression using short interfering nucleic acid (siNA)
US20050182006A1 (en) * 2001-05-18 2005-08-18 Sirna Therapeutics, Inc RNA interference mediated inhibition of protein kinase C alpha (PKC-alpha) gene expression using short interfering nucleic acid (siNA)
US20050176665A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hairless (HR) gene expression using short interfering nucleic acid (siNA)
US20060211642A1 (en) * 2001-05-18 2006-09-21 Sirna Therapeutics, Inc. RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA)
US20050164967A1 (en) * 2001-05-18 2005-07-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
US20080161256A1 (en) * 2001-05-18 2008-07-03 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20050014172A1 (en) * 2002-02-20 2005-01-20 Ivan Richards RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
US20050137155A1 (en) * 2001-05-18 2005-06-23 Sirna Therapeutics, Inc. RNA interference mediated treatment of Parkinson disease using short interfering nucleic acid (siNA)
US20050203040A1 (en) * 2001-05-18 2005-09-15 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
US20050267058A1 (en) * 2001-05-18 2005-12-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (sINA)
US20050054598A1 (en) * 2002-02-20 2005-03-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition hairless (HR) gene expression using short interfering nucleic acid (siNA)
US20050079610A1 (en) * 2001-05-18 2005-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)
US20050130181A1 (en) * 2001-05-18 2005-06-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of wingless gene expression using short interfering nucleic acid (siNA)
US20060142226A1 (en) * 2001-05-18 2006-06-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of cholesteryl ester transfer protein (CETP) gene expression using short interfering nucleic acid (siNA)
US7517864B2 (en) * 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050159379A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc RNA interference mediated inhibition of gastric inhibitory polypeptide (GIP) and gastric inhibitory polypeptide receptor (GIPR) gene expression using short interfering nucleic acid (siNA)
US20050233997A1 (en) * 2001-05-18 2005-10-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
US20050143333A1 (en) * 2001-05-18 2005-06-30 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
US20050233996A1 (en) * 2002-02-20 2005-10-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hairless (HR) gene expression using short interfering nucleic acid (siNA)
JP4358521B2 (ja) * 2001-05-18 2009-11-04 サーナ・セラピューティクス・インコーポレイテッド 細胞デリバリーのためのコンジュゲートおよび組成物
US20050191638A1 (en) * 2002-02-20 2005-09-01 Sirna Therapeutics, Inc. RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US20050159376A1 (en) * 2002-02-20 2005-07-21 Slrna Therapeutics, Inc. RNA interference mediated inhibition 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA)
US20050119211A1 (en) * 2001-05-18 2005-06-02 Sirna Therapeutics, Inc. RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA)
US20050080031A1 (en) * 2001-05-18 2005-04-14 Sirna Therapeutics, Inc. Nucleic acid treatment of diseases or conditions related to levels of Ras, HER2 and HIV
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20050153914A1 (en) * 2001-05-18 2005-07-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of MDR P-glycoprotein gene expression using short interfering nucleic acid (siNA)
US20050124566A1 (en) * 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
US20050153915A1 (en) * 2001-05-18 2005-07-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of early growth response gene expression using short interfering nucleic acid (siNA)
US20050233344A1 (en) * 2001-05-18 2005-10-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid (siNA)
US20050164966A1 (en) * 2001-05-18 2005-07-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of type 1 insulin-like growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050164968A1 (en) * 2001-05-18 2005-07-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of ADAM33 gene expression using short interfering nucleic acid (siNA)
US20050124567A1 (en) * 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TRPM7 gene expression using short interfering nucleic acid (siNA)
US20030130186A1 (en) * 2001-07-20 2003-07-10 Chandra Vargeese Conjugates and compositions for cellular delivery
US20050182007A1 (en) * 2001-05-18 2005-08-18 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
US20070042983A1 (en) * 2001-05-18 2007-02-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20080188430A1 (en) * 2001-05-18 2008-08-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
US20050159382A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
US20050196765A1 (en) * 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
US20070270579A1 (en) * 2001-05-18 2007-11-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20050119212A1 (en) * 2001-05-18 2005-06-02 Sirna Therapeutics, Inc. RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA)
US20050256068A1 (en) * 2001-05-18 2005-11-17 Sirna Therapeutics, Inc. RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA)
US20050164224A1 (en) * 2001-05-18 2005-07-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
US20050176666A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GPRA and AAA1 gene expression using short interfering nucleic acid (siNA)
US20050124568A1 (en) * 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of acetyl-CoA-carboxylase gene expression using short interfering nucleic acid (siNA)
US7109165B2 (en) * 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US20050288242A1 (en) * 2001-05-18 2005-12-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
US7803915B2 (en) * 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
US20050107595A1 (en) * 2001-06-20 2005-05-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
DK2000545T3 (da) 2001-06-20 2011-11-28 Genentech Inc Sammensætninger og fremgangsmåder til diagnose og behandling af lunge-tumor
CA2451643C (en) 2001-06-21 2012-11-13 Isis Pharmaceuticals, Inc. Antisense modulation of superoxide dismutase 1, soluble expression
US20030031677A1 (en) * 2001-06-25 2003-02-13 Drug Innovation & Design, Incorporated Exponential pattern recognition based cellular targeting, compositions, methods and anticancer applications
US7425545B2 (en) 2001-07-25 2008-09-16 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
US6964950B2 (en) 2001-07-25 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of C-reactive protein expression
US20030096772A1 (en) 2001-07-30 2003-05-22 Crooke Rosanne M. Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
CA2460120A1 (en) 2001-09-18 2003-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
DK1434603T3 (da) * 2001-09-28 2010-04-26 Purdue Research Foundation Fremgangsmåde til behandling ved anvendelse af ligand-immunogen-konjugater
ATE516364T1 (de) 2001-10-09 2011-07-15 Isis Pharmaceuticals Inc Antisense-modulation der expression des insulinähnlicher-wachstumsfaktor-bindungsprotei s 5
US6750019B2 (en) 2001-10-09 2004-06-15 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
AU2002368202B2 (en) 2001-11-02 2008-06-05 Insert Therapeutics, Inc Methods and compositions for therapeutic use of RNA interference
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
US7255874B1 (en) 2001-12-21 2007-08-14 Closure Medical Corporation Biocompatible polymers and adhesives: compositions, methods of making and uses related thereto
US7261875B2 (en) * 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
JP2005525095A (ja) 2002-01-02 2005-08-25 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
US8043602B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8043603B2 (en) * 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20050096284A1 (en) * 2002-02-20 2005-05-05 Sirna Therapeutics, Inc. RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20050137153A1 (en) * 2002-02-20 2005-06-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of alpha-1 antitrypsin (AAT) gene expression using short interfering nucleic acid (siNA)
US20050222064A1 (en) * 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
US20030191075A1 (en) * 2002-02-22 2003-10-09 Cook Phillip Dan Method of using modified oligonucleotides for hepatic delivery
US20030180712A1 (en) 2002-03-20 2003-09-25 Biostratum Ab Inhibition of the beta3 subunit of L-type Ca2+ channels
ES2649817T3 (es) 2002-04-05 2018-01-15 Roche Innovation Center Copenhagen A/S Compuestos oligom¿¿ricos para la modulaci¿®n de la expresi¿®n de HIF-1¿Á
AU2003230874A1 (en) 2002-04-16 2003-11-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2003224989B2 (en) * 2002-04-19 2008-12-04 Endocyte, Inc. Adjuvant enhanced immunotherapy
US20030206916A1 (en) * 2002-05-03 2003-11-06 Rush-Presbyterian-St. Luke's Medical Center Immunogenic peptides
EP1549352A4 (de) 2002-05-06 2005-07-27 Nucleonics Inc Verfahren zur abgabe von nukleinsäuren
AU2003243226A1 (en) * 2002-05-15 2003-12-02 Endocyte, Inc. Vitamin-mitomycin conjugates
US7199107B2 (en) 2002-05-23 2007-04-03 Isis Pharmaceuticals, Inc. Antisense modulation of kinesin-like 1 expression
ATE522130T1 (de) 2002-07-19 2011-09-15 Univ South Carolina Zusammensetzungen und verfahren zur modulation der genexpression in pflanzen
EP2036984B1 (de) 2002-07-26 2012-02-22 BASF Plant Science GmbH Revertierung der negativ-selektiven Wirkung von negativen Markerproteinen als Selektionsverfahren
BRPI0314042B8 (pt) 2002-09-06 2021-05-25 Calando Pharmaceuticals Inc polímeros à base de ciclodextrina para o fornecimento de agentes terapêuticos ligados a eles por covalência
BR0314236A (pt) 2002-09-13 2005-08-09 Replicor Inc Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos
EP2272958A1 (de) 2002-09-26 2011-01-12 ISIS Pharmaceuticals, Inc. Modulierung von der Forkheadbox O1A-Expression
EA021644B1 (ru) 2002-10-17 2015-08-31 Генмаб А/С Человеческое моноклональное антитело против cd20 и его применение
AU2003304203A1 (en) * 2002-10-29 2005-01-04 Pharmacia Corporation Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
WO2004044138A2 (en) 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
CA2504929C (en) 2002-11-05 2014-07-22 Charles Allerson Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
BR0316046A (pt) * 2002-11-07 2005-09-13 Univ Texas Conjugados de fármaco e etilenodicisteìna (ec), composições e métodos para imageamento de doença especìfica de tecido
AU2003290718A1 (en) * 2002-11-12 2004-07-22 The Research Foundation Of The State University Of New York TRANSLATIONAL CONTROL BY SMALL, NON-TRANSLATABLE RNAs
JP4986109B2 (ja) 2002-11-13 2012-07-25 ジェンザイム・コーポレーション アポリポタンパク質ｂ発現のアンチセンス調節
DK1569695T3 (da) 2002-11-13 2013-08-05 Genzyme Corp Antisense-modulering af apolipoprotein-b-ekspression
AU2002953073A0 (en) * 2002-11-21 2003-01-16 Access Pharmaceuticals Australia Pty Limited Amplification of biotin-mediated targeting
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US7144999B2 (en) 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
US20040231231A1 (en) * 2002-12-20 2004-11-25 Cataldo Dominic A. Use of colloidal clays for sustained release of active ingredients
EP2517730A3 (de) 2003-01-27 2013-01-02 Endocyte, Inc. Vitaminrezeptorbindende Wirkstofffreisetzungskonjugate
US7713738B2 (en) 2003-02-10 2010-05-11 Enzon Pharmaceuticals, Inc. Oligomeric compounds for the modulation of survivin expression
DK1597366T3 (da) 2003-02-11 2013-02-25 Antisense Therapeutics Ltd Modulering af ekspression af insulin-lignende vækstfaktor receptor I
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
EP1620112A4 (de) * 2003-04-17 2007-04-25 Univ Columbia Desmoglein 4 ist ein neues gen, das am haarwachstum beteiligt ist
NZ542988A (en) 2003-04-23 2008-07-31 Medarex Inc Humanised antibodies directed against the IFNAR-1 receptor in which murine CDR sequences have been grafted directly into unmodified human framework sequences, resulting in high affinity, functional antibodies
US7399853B2 (en) 2003-04-28 2008-07-15 Isis Pharmaceuticals Modulation of glucagon receptor expression
JP2007526238A (ja) * 2003-05-06 2007-09-13 パーデュー・リサーチ・ファウンデーション マクロファージまたは葉酸受容体を標的とする狼瘡治療法
WO2004110250A2 (en) * 2003-05-30 2004-12-23 Purdue Research Foundation Diagnostic method for atherosclerosis
IL156263A0 (en) * 2003-06-02 2004-01-04 Hadasit Med Res Service Livin-derived peptides, compositions and uses thereof
AU2004253455B2 (en) 2003-06-03 2011-03-03 Eli Lilly And Company Modulation of survivin expression
WO2005002508A2 (en) * 2003-06-11 2005-01-13 Access Pharmaceuticals, Inc. Macromolecular platinum chelates
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7414076B2 (en) * 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
WO2005007673A2 (en) * 2003-07-03 2005-01-27 Rush University Medical Center Immunogenic peptides
EP1502954A1 (de) 2003-07-31 2005-02-02 greenovation Biotech GmbH Gebrauch von Konstrukten mit rekombinanten Sequenzmotifen zur Erhöhung der Genexpression in Moosen
CA2533701A1 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
US20070123480A1 (en) * 2003-09-11 2007-05-31 Replicor Inc. Oligonucleotides targeting prion diseases
SG146682A1 (en) 2003-09-18 2008-10-30 Isis Pharmaceuticals Inc Modulation of eif4e expression
US7662929B2 (en) 2003-10-10 2010-02-16 Alchemia Oncology Pty Limited Antibody that specifically binds hyaluronan synthase
US20050191653A1 (en) 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
WO2005046730A2 (en) * 2003-11-12 2005-05-26 The University Of Georgia Research Foundation, Inc. Biotin-facilitated transport into gram negative bacteria
CA2747871C (en) 2003-11-17 2018-04-10 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US20050118124A1 (en) * 2003-12-01 2005-06-02 Reinhart Gale M. Compositions for treating keratinous surfaces
KR20060135690A (ko) 2003-12-10 2006-12-29 메다렉스, 인코포레이티드 Ｉｐ―１０ 항체 및 그의 용도
KR101151477B1 (ko) 2003-12-10 2012-06-22 메다렉스, 인코포레이티드 인터페론 알파 항체 및 그의 용도
US9050378B2 (en) * 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
FR2864085B1 (fr) * 2003-12-18 2010-09-17 Centre Nat Rech Scient Nouveaux modulateurs du proteasome
DE602004027163D1 (de) 2003-12-23 2010-06-24 Santaris Pharma As Oligomere verbindungen zur modulation von bcl-2
WO2005071080A2 (en) 2004-01-20 2005-08-04 Isis Pharmaceuticals, Inc. Modulation of glucocorticoid receptor expression
US7468431B2 (en) * 2004-01-22 2008-12-23 Isis Pharmaceuticals, Inc. Modulation of eIF4E-BP2 expression
US20050261170A1 (en) * 2004-01-22 2005-11-24 Immunomedics, Inc. Folate conjugates and complexes
EP2816351A3 (de) * 2004-01-27 2015-03-25 Compugen Ltd. Verfahren und Systeme zur Annotation biomolekularer Sequenzen
EP3101034A1 (de) 2004-02-12 2016-12-07 Morphotek, Inc. Monoklonale, spezifisch an folatrezeptor-alpha bindende antikörper
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
EP2700720A3 (de) 2004-03-15 2015-01-28 Isis Pharmaceuticals, Inc. Zusammensetzungen und Verfahren zur Optimierung der Spaltung von RNA durch RNase H
US10858384B2 (en) 2004-03-22 2020-12-08 Kode Biotech Limited Synthetic molecule constructs
NZ587442A (en) 2004-03-22 2012-02-24 Kode Biotech Ltd Synthetic molecule constructs
CA2561221C (en) * 2004-03-26 2016-09-20 Curis, Inc. Rna interference modulators of hedgehog signaling and uses thereof
WO2006073419A2 (en) * 2004-04-01 2006-07-13 Gang Zheng Lipoprotein nanoplatforms
US20050244869A1 (en) * 2004-04-05 2005-11-03 Brown-Driver Vickie L Modulation of transthyretin expression
CA2562151C (en) * 2004-04-30 2016-09-06 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a c5-modified pyrimidine
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US7524827B2 (en) 2004-06-01 2009-04-28 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
US20050272100A1 (en) * 2004-06-02 2005-12-08 Arthur Karlin Separation and quantification of biotinylated macromolecules
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
JP2008501335A (ja) * 2004-06-03 2008-01-24 アイシス ファーマシューティカルズ、インク． キメラギャップ化オリゴマー組成物
US20090048192A1 (en) * 2004-06-03 2009-02-19 Isis Pharmaceuticals, Inc. Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
AU2005252663B2 (en) * 2004-06-03 2011-07-07 Isis Pharmaceuticals, Inc. Double strand compositions comprising differentially modified strands for use in gene modulation
ES2660765T3 (es) 2004-06-21 2018-03-26 The Board Of Trustees Of The Leland Stanford Junior University Genes y rutas expresadas de forma diferencial en trastorno bipolar y/o trastorno depresivo mayor
ES2526194T3 (es) 2004-06-21 2015-01-08 E. R. Squibb & Sons, L.L.C. Anticuerpos del receptor 1 de interferón alfa, y sus usos
JP5149620B2 (ja) 2004-07-23 2013-02-20 エンドサイト，インコーポレイテッド ２価リンカーおよびその結合体
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
ATE514776T1 (de) 2004-10-05 2011-07-15 California Inst Of Techn Aptamer-regulierte nukleinsäuren und verwendungen davon
WO2006050734A2 (en) * 2004-11-09 2006-05-18 Santaris Pharma A/S Potent lna oligonucleotides for the inhibition of hif-1a expression
WO2006050732A2 (en) * 2004-11-09 2006-05-18 Santaris Pharma A/S Lna oligonucleotides and the treatment of cancer
US9447138B2 (en) 2004-11-09 2016-09-20 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
EP2116603A3 (de) 2004-11-12 2010-02-17 The University Of British Columbia Antimikrobielle Peptide
CA2586111A1 (en) * 2004-11-12 2006-06-08 Neurochem (International) Limited Methods and fluorinated compositions for treating amyloid-related diseases
EP1817305A2 (de) * 2004-11-16 2007-08-15 Neurochem (International) Limited Verbindungen zur behandlung von cns- und amyloidassoziierten krankheiten
WO2006085149A2 (en) * 2004-12-22 2006-08-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
ES2731448T3 (es) * 2004-12-23 2019-11-15 Purdue Research Foundation Procedimiento de análisis por imagen mediante tomografía por emisión de positrones
CA2596506C (en) 2005-02-09 2021-04-06 Avi Biopharma, Inc. Antisense composition and method for treating muscle atrophy
RU2007137489A (ru) 2005-03-10 2009-04-20 Дженентек, Инк. (Us) Способы и композиции для модуляции целостности сосудов
JP5289935B2 (ja) 2005-03-16 2013-09-11 エンドサイト，インコーポレイテッド プテロイン酸およびその結合体の合成と精製
CA2602375C (en) 2005-03-23 2018-07-24 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
ATE541928T1 (de) 2005-03-31 2012-02-15 Calando Pharmaceuticals Inc Inhibitoren der untereinheit 2 der ribonukleotidreduktase und ihre verwendungen
CA2607444C (en) 2005-04-22 2015-03-10 Morphotek, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
CA2607147C (en) 2005-05-09 2018-07-17 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
EP1899379B1 (de) 2005-06-20 2018-04-11 E. R. Squibb & Sons, L.L.C. Cd19-antikörper und anwendungen davon
AU2006265108C1 (en) 2005-07-01 2013-01-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
US20070009434A1 (en) * 2005-07-05 2007-01-11 Low Philip S Imaging and therapeutic method using monocytes
US20090176725A1 (en) * 2005-08-17 2009-07-09 Sirna Therapeutics Inc. Chemically modified short interfering nucleic acid molecules that mediate rna interference
JP2009504783A (ja) * 2005-08-19 2009-02-05 エンドサイト，インコーポレイテッド ビンカアルカロイド、類似体および誘導体のリガンド結合体
RU2470668C2 (ru) * 2005-08-19 2012-12-27 Эндосайт, Инк. Конъюгаты лиганда с несколькими лекарственными средствами
US8507439B2 (en) 2005-08-29 2013-08-13 Angela Shashoua Neuroprotective and neurorestorative method and compositions
EP1762575A1 (de) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identifizierung Tumor-assoziierter Antigene für Diagnoseund Therapie
JP2009507499A (ja) * 2005-09-15 2009-02-26 サンタリス ファーマ アー／エス Ａｐｏ−ｂ１００発現の抑制のためのｒｎａアンタゴニスト化合物
EP1940473A2 (de) * 2005-09-23 2008-07-09 Purdue Research Foundation Verfahren und vorrichtung für die multiphotonen-in-vivo-durchflusszytometrie
BRPI0617549A2 (pt) 2005-09-26 2011-07-26 Medarex Inc anticorpo monoclonal humano isolado, anticorpo monoclonal humano isolado ou uma porÇço ligante ao antÍgeno do mesmo, composiÇço, imunoconjugado, molÉcula de Ácido nuclÉico isolada, vetor de expressço, cÉlula hospedeira, mÉtodo para preparar um anticorpo anti-cd70, mÉtodo para tratar ou prevenir uma doenÇa, mÉtodo para tratar uma doenÇa autoimune em um indivÍduo, mÉtodo para tratar uma inflamaÇço em um indivÍduo, mÉtodo para tratar uma infecÇço viral em um indivÍduo, anticorpo ou porÇço ligante ao antÍgeno do mesmo e uso de um anticorpo ou de uma porÇço ligante ao antÍgeno do mesmo
EP2532679B1 (de) 2005-10-21 2017-04-12 Novartis AG Menschliche Antikörper gegen IL13 und therapeutische Verwendungen
US20070099246A1 (en) * 2005-11-03 2007-05-03 Sandy John D Antibodies, assays and kits to quantitate cartilage destruction
JP5366554B2 (ja) 2005-11-12 2013-12-11 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー うつを診断および処置するためのｆｇｆ２関連方法
CA2630602A1 (en) 2005-11-21 2007-05-31 Isis Pharmaceuticals, Inc. Modulation of eif4e-bp2 expression
EP1790664A1 (de) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoklonale Antikörper gegen Claudin-18 zur Behandlung von Krebs
WO2007064945A2 (en) 2005-12-01 2007-06-07 Pronai Therapeutics, Inc. Cancer therapies and pharmaceutical compositions used therein
CN101356195B (zh) 2005-12-08 2013-04-03 米德列斯公司 抗岩藻糖基-gm1的人单克隆抗体及使用抗岩藻糖基-gm1抗体的方法
IL173104A0 (en) 2006-01-12 2006-06-11 Yeda Res & Dev Siva and ubiquintination
EP1976883B1 (de) 2006-01-17 2012-10-03 Medarex, Inc. Monoklonale antikörper gegen cd30 ohne fucosyl- und xylosylreste
SI2161038T1 (sl) 2006-01-26 2014-05-30 Isis Pharmaceuticals, Inc. Sestavki in njihove uporabe, usmerjeni proti huntingtinu
US8168164B2 (en) * 2006-02-03 2012-05-01 Purdue Research Foundation Targeted conjugates and radiation
GB0603683D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
US20070232556A1 (en) * 2006-03-31 2007-10-04 Montine Thomas J Methods and compositions for the treatment of neurological diseases and disorders
EP2614839A3 (de) 2006-04-05 2015-01-28 Genentech, Inc. Verfahren zur Verwendung von BOC/CDO zur Modulation der Hedgehog-Signalisierung
US8758723B2 (en) 2006-04-19 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
AU2007240732B2 (en) * 2006-04-21 2013-07-04 Amgen, Inc. Buffering agents for biopharmaceutical formulations
WO2007124077A2 (en) 2006-04-21 2007-11-01 Amgen, Inc. Immunoglobulin constant region domains with enhanced stability
US20070258941A1 (en) * 2006-05-02 2007-11-08 Pfister Brian E Methods and compositions for remediation of disc herniation by modifying structure
US20070259820A1 (en) * 2006-05-03 2007-11-08 The Regents Of The University Of Michigan Methods and reagents for activating heat shock protein 70
CN101437943A (zh) * 2006-05-03 2009-05-20 波罗的科技发展有限公司 牢固结合的碱基-修饰的寡核苷酸和人工核酸酶组合的反义药剂
WO2007137301A2 (en) * 2006-05-23 2007-11-29 Isis Pharmaceuticals, Inc. Modulation of chrebp expression
US20100226967A1 (en) * 2006-05-23 2010-09-09 Purdue Research Foundation Imaging and therapeutic method using progenitor cells
PE20080316A1 (es) * 2006-05-25 2008-04-10 Bristol Myers Squibb Co Compuestos de aziridinil-epotilona
AR062448A1 (es) * 2006-05-25 2008-11-12 Endocyte Inc Conjugados de analogos de aziridinil-epotilona y composiciones farmaceuticas que comprenden los mismos
ES2286951B1 (es) * 2006-05-26 2008-10-01 Instituto Cientifico Y Tecnologico De Navarra, S.A Nanoparticulas bioadhesivas para la administracion de moleculas biologicamente activas.
ES2381731T3 (es) 2006-06-28 2012-05-31 Yeda Research And Development Co. Ltd. Caspasa-8 y cicatrización de heridas
WO2008011473A2 (en) 2006-07-19 2008-01-24 Isis Pharmaceuticals, Inc. Compositions and their uses directed to hbxip
WO2008019394A2 (en) * 2006-08-11 2008-02-14 The Government Of The United States Of America As Represented By The Secretary, Dept Of Health And Human Services Methods for treatment and diagnosis of psychiatric disorders
MX2009002418A (es) 2006-09-05 2009-04-23 Medarex Inc Anticuerpos para las proteinas morfogenicas oseas y receptores de estas y metodos para su uso.
RS55740B1 (sr) 2006-10-02 2017-07-31 Squibb & Sons Inc Humana antitela koja se vezuju za cxcr4 i njihove upotrebe
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
JP5631591B2 (ja) * 2006-10-06 2014-11-26 アムジエン・インコーポレーテツド 安定な抗体製剤
EP2089417B1 (de) 2006-10-12 2014-12-31 BHI Limited Partnership Verfahren, verbindungen, zusammensetzungen und vehikel zur verabreichung von 3-amino-1-propansulfonsäure
EP2094247B1 (de) * 2006-10-20 2022-06-29 Amgen Inc. Stabile polypeptid-formulierungen
US8618248B2 (en) 2006-10-31 2013-12-31 President And Fellows Of Harvard College Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides
CA2668197A1 (en) 2006-11-03 2008-05-15 Philip S. Low Ex vivo flow cytometry method and device
WO2008058291A2 (en) * 2006-11-09 2008-05-15 California Institute Of Technology Modular aptamer-regulated ribozymes
CN101578296A (zh) 2006-11-15 2009-11-11 梅达雷克斯公司 结合btla的人类单克隆抗体及使用方法
CN103172743B (zh) 2006-12-01 2015-04-08 梅达雷克斯有限责任公司 结合cd22的人抗体及其用途
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
AU2007333098A1 (en) 2006-12-14 2008-06-19 Medarex, Inc. Human antibodies that bind CD70 and uses thereof
EP2118118B1 (de) * 2007-01-19 2017-09-27 Exiqon A/S Vermittelte zelluläre verabreichung von lna-oligonukleotiden
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
WO2008094945A2 (en) 2007-01-29 2008-08-07 Isis Pharmaceuticals, Inc. Compounds and methods for modulating protein expression
EP2567711A3 (de) 2007-02-07 2013-05-01 Purdue Research Foundation Bildgebungsverfahren für Positronenemissionstomographie
US20100104626A1 (en) 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
EP2716301B1 (de) 2007-02-16 2017-04-05 Merrimack Pharmaceuticals, Inc. Antikörper gegen erbb3 und verwendungen davon
CN101663407B (zh) 2007-02-22 2017-08-08 健泰科生物技术公司 用于检测炎性肠病的方法
EP1970384A1 (de) * 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoklonale Antikörper zur Krebsbehandlung
CN103948937A (zh) * 2007-03-14 2014-07-30 恩多塞特公司 结合配体连接的微管溶素递药缀合物
US8153863B2 (en) 2007-03-23 2012-04-10 New York University Transgenic plants expressing GLK1 and CCA1 having increased nitrogen assimilation capacity
CN101679974B (zh) 2007-03-27 2015-09-30 航道生物技术有限责任公司 包含抗体替代轻链序列的构建体和文库
US8211860B2 (en) * 2007-04-27 2012-07-03 Kode Biotech Limited Carbohydrate-lipid constructs and their use in preventing or treating viral infection
GB0709835D0 (en) 2007-05-22 2007-07-04 Plant Bioscience Ltd Composition and method for modulating plant root hair development
EP3351270A1 (de) 2007-05-23 2018-07-25 The Trustees of the University of Pennsylvania Gezielte träger zur intrazellulären arzneimittelabgabe
US8961926B2 (en) * 2007-05-25 2015-02-24 Purdue Research Foundation Method of imaging localized infections
EP2152717A1 (de) 2007-05-25 2010-02-17 Bristol-Myers Squibb Company Verfahren zur herstellung von epothilonverbindungen und analoga
EP1997832A1 (de) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoklonale Antikörper gegen Claudin-18 zur Behandlung von Krebs
RU2523909C2 (ru) * 2007-06-25 2014-07-27 Эндосайт, Инк. Конъюгаты, содержащие гидрофильные спейсеры линкеров
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
WO2009011855A2 (en) * 2007-07-16 2009-01-22 California Institute Of Technology Selection of nucleic acid-based sensor domains within nucleic acid switch platform
EP2626371A1 (de) 2007-07-31 2013-08-14 MedImmune, LLC Multispezifische Epitopbindeproteine und ihre Verwendungen
WO2009097006A2 (en) 2007-08-10 2009-08-06 Medarex, Inc. Hco32 and hco27 and related examples
US20120165387A1 (en) 2007-08-28 2012-06-28 Smolke Christina D General composition framework for ligand-controlled RNA regulatory systems
US8367815B2 (en) * 2007-08-28 2013-02-05 California Institute Of Technology Modular polynucleotides for ligand-controlled regulatory systems
US8394391B2 (en) * 2007-08-31 2013-03-12 University Of Utah Research Foundation Drug delivery vehicle that mimics viral properties
LT2769729T (lt) 2007-09-04 2019-05-10 Compugen Ltd. Polipeptidai ir polinukleotidai ir jų panaudojimas kaip vaistų taikinio vaistų ir biologinių preparatų gamybai
US8865667B2 (en) * 2007-09-12 2014-10-21 California Institute Of Technology Higher-order cellular information processing devices
JP2010539978A (ja) 2007-10-02 2010-12-24 アムジェン インコーポレイテッド マイクロ−ｒｎａおよびその前駆体にハイブリダイズしうる核酸を用いるエリスロポエチンの増加
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
US9187521B2 (en) 2007-10-25 2015-11-17 Endocyte, Inc. Tubulysins and processes for preparing
KR20100091170A (ko) 2007-11-02 2010-08-18 노파르티스 아게 저밀도-지단백질 수용체-관련 단백질 ６ (ｌｒｐ６)을 조정하기 위한 분자 및 방법
JP2011502502A (ja) * 2007-11-05 2011-01-27 バルティック テクロノジー デヴェロプメント，リミテッド 核酸のハイブリッド形成における修飾塩基を含むオリゴヌクレオチドの使用
NZ585556A (en) 2007-11-07 2012-07-27 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
CN101903037A (zh) * 2007-11-15 2010-12-01 恩多塞特公司 施用偶合物的方法
WO2009067820A1 (en) 2007-11-27 2009-06-04 The University Of British Columbia 14-3-3 antagonists for the prevention and treatment of arthritis
EP2231194B1 (de) 2007-12-04 2017-02-22 Alnylam Pharmaceuticals Inc. Folat-irna-konjugate
AU2008340355B2 (en) 2007-12-04 2015-01-22 Tekmira Pharmaceuticals Corporation Targeting lipids
US9029524B2 (en) * 2007-12-10 2015-05-12 California Institute Of Technology Signal activated RNA interference
AU2009205995B2 (en) 2008-01-18 2014-04-03 Medimmune, Llc Cysteine engineered antibodies for site-specific conjugation
CN101970006B (zh) 2008-02-05 2014-08-06 百时美施贵宝公司 α5-β1抗体和它们的用途
MX2010008578A (es) 2008-02-08 2010-11-10 Medimmune Llc Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc.
EP2252314B1 (de) 2008-02-27 2014-04-09 Temple University - Of The Commonwealth System of Higher Education Leptin-agonist und anwendungsverfahren
WO2009114085A2 (en) 2008-03-03 2009-09-17 The University Of Miami Allogeneic cancer cell-based immunotherapy
AU2009226077B2 (en) 2008-03-20 2012-04-19 University Of Miami Heat shock protein gp96 vaccination and methods of using same
EP2283133A2 (de) 2008-04-04 2011-02-16 Calando Pharmaceuticals, Inc. Zusammensetzungen und verwendung von epas1-inhibitoren
JP5788312B2 (ja) 2008-04-11 2015-09-30 アルニラム ファーマスーティカルズ インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 標的リガンドをエンドソーム分解性成分と組み合わせることによる核酸の部位特異的送達
US10485879B2 (en) 2008-04-15 2019-11-26 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Plasma cell cytokine vehicle containing fusion proteins for targeted introduction of siRNA into cells and tissues
US8703921B2 (en) 2008-04-15 2014-04-22 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Compositions and methods for delivering inhibitory oligonucleotides
ES2620285T3 (es) 2008-05-02 2017-06-28 Novartis Ag Moléculas de unión con base en fibronectina mejorada y usos de las mismas
MX2010012931A (es) 2008-05-30 2011-02-24 Dana Farber Cancer Inst Inc Metodos para tratar una enfermedad asociada con quinesina meiotica.
WO2010008582A2 (en) 2008-07-18 2010-01-21 Rxi Pharmaceuticals Corporation Phagocytic cell drug delivery system
EP2323667A4 (de) * 2008-08-07 2012-07-25 Isis Pharmaceuticals Inc Modulierung der transthyretin-expression durch behandlung von zns-erkrankungen
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
JP5420668B2 (ja) 2008-08-25 2014-02-19 エクスカリアード・ファーマシューティカルズ，インコーポレイテッド 結合組織成長因子を対象とするアンチセンスオリゴヌクレオチドおよびその使用
EP2166021A1 (de) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoklonale Antikörper zur Krebsbehandlung
CA2753338A1 (en) 2008-09-22 2010-03-25 Rxi Pharmaceuticals Corporation Neutral nanotransporters
CA2998281C (en) 2008-09-26 2022-08-16 Dana-Farber Cancer Institute, Inc. Human anti-pd-1 antobodies and uses therefor
WO2010035261A2 (en) 2008-09-29 2010-04-01 Ben Gurion University Of The Negev Research And Development Authority Amyloid beta-peptides and methods of use thereof
GB2465749B (en) 2008-11-25 2013-05-08 Algentech Sas Plant cell transformation method
GB2465748B (en) 2008-11-25 2012-04-25 Algentech Sas Plant cell transformation method
WO2010065662A2 (en) 2008-12-04 2010-06-10 Curna, Inc. Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1
RU2746478C2 (ru) 2008-12-04 2021-04-14 КьюРНА, Инк. Лечение связанных с геном-супрессором опухолей заболеваний посредством ингибирования природного транскрипта в антисмысловой ориентации относительно этого гена
KR101829469B1 (ko) 2008-12-04 2018-03-30 큐알엔에이, 인크. Ｅｐｏ에 대한 천연 안티센스 전사체의 억제에 의해 에리트로포에틴(ｅｐｏ) 관련된 질환의 치료
EP2373690B1 (de) 2008-12-08 2015-02-11 Compugen Ltd. Tmem154-spezifische antikörper
WO2010078536A1 (en) 2009-01-05 2010-07-08 Rxi Pharmaceuticals Corporation Inhibition of pcsk9 through rnai
GB2467167B (en) 2009-01-26 2013-09-11 Algentech Sas Gene targeting in plants
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
KR101682735B1 (ko) 2009-02-12 2016-12-06 큐알엔에이, 인크. 뇌 유래된 신경영양성 인자 (ｂｄｎｆ)에 대한 자연 안티센스 전사체의 저해에 의한 뇌 유래된 신경영양성 인자 (ｂｄｎｆ) 관련된 질환의 치료
ES2658626T3 (es) 2009-02-12 2018-03-12 Curna, Inc. Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de células gliales (GDNF) por inhibición de transcrito antisentido natural a GDNF
US8329882B2 (en) 2009-02-18 2012-12-11 California Institute Of Technology Genetic control of mammalian cells with synthetic RNA regulatory systems
JP6250263B2 (ja) 2009-03-04 2017-12-20 クルナ・インコーポレーテッド サーチュイン１（ｓｉｒｔ１）に対する天然アンチセンス転写物の抑制によるｓｉｒｔ１関連疾患の治療
JP5816558B2 (ja) 2009-03-05 2015-11-18 メダレックス・リミテッド・ライアビリティ・カンパニーＭｅｄａｒｅｘ， Ｌ．Ｌ．Ｃ． Ｃａｄｍ１に特異的な完全ヒト抗体
ES2656290T3 (es) 2009-03-16 2018-02-26 Curna, Inc. Tratamiento de enfermedades relacionadas con el factor nuclear (derivado de eritroide 2) similar al 2 (NRF2) mediante inhibición del transcrito antisentido natural a NRF2
EP2408920B1 (de) 2009-03-17 2017-03-08 CuRNA, Inc. Behandlung von erkrankungen im zusammenhang mit dem delta-like-1-homolog (dlk1) mittels hemmung des natürlichen antisense-transkripts gegen dlk1
US9045557B2 (en) 2009-03-18 2015-06-02 Oncotherapy Science, Inc. NEIL3 peptides and vaccines including the same
US9145555B2 (en) 2009-04-02 2015-09-29 California Institute Of Technology Integrated—ligand-responsive microRNAs
MA33276B1 (fr) 2009-04-20 2012-05-02 Oxford Biotherapeutics Ltd Anticorps spécifiques à la cadhérine-17
EP3524275A1 (de) 2009-04-22 2019-08-14 Massachusetts Institute Of Technology Angeborene immununterdrückung ermöglicht die wiederholte verabreichung von langen rna-molekülen
NO2424895T3 (de) 2009-04-27 2018-02-03
BRPI1016055A2 (pt) 2009-04-27 2016-05-10 Novartis Ag composição e métodos de uso para anticorpos terapêuticos específicos para a subunidade beta i do receptor de il-12
EP2424987B1 (de) 2009-05-01 2017-11-15 CuRNA, Inc. Behandlung von hämoglobin (hbf / hbg) verwandten krankheiten durch die inhibition des natürlichen antisense transcripts zu hbf / hbg
KR20120088550A (ko) 2009-05-04 2012-08-08 애보트 리서치 비.브이. 증진된 생체내 안정성을 갖는 신경 성장 인자(ｎｇｆ)에 대한 항체
JP5883782B2 (ja) 2009-05-06 2016-03-15 クルナ・インコーポレーテッド 脂質輸送代謝遺伝子に対する天然アンチセンス転写物の抑制による脂質輸送代謝遺伝子関連疾患の治療
WO2010129746A2 (en) 2009-05-06 2010-11-11 Curna, Inc. Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
US20120128671A1 (en) 2009-05-13 2012-05-24 Lawrence Horowitz Neutralizing molecules to influenza viruses
DK2432881T3 (en) 2009-05-18 2018-02-26 Curna Inc TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR
EP2432499A2 (de) 2009-05-20 2012-03-28 Schering Corporation Modulation von pilr-rezeptoren zur behandlung mikrobieller infektionen
KR101703695B1 (ko) 2009-05-22 2017-02-08 큐알엔에이, 인크. 전사 인자 ｅ3(ｔｆｅ3)에 대한 천연 안티센스 전사체의 억제에 의해 ｔｆｅ3 및 인슐린 수용체 기질 2(ｉｒｓ2)의 치료
TWI507204B (zh) 2009-05-26 2015-11-11 Oncotherapy Science Inc Ｃｄｃ４５ｌ胜肽與含此胜肽之疫苗
CN103221541B (zh) 2009-05-28 2017-03-01 库尔纳公司 通过抑制抗病毒基因的天然反义转录物来治疗抗病毒基因相关疾病
CA2765357A1 (en) 2009-06-15 2010-12-23 Plant Bioscience Limited Production of viral capsids
JP6128846B2 (ja) 2009-06-16 2017-05-17 クルナ・インコーポレーテッド パラオキソナーゼ（ｐｏｎ１）に対する天然アンチセンス転写物の抑制によるｐｏｎ１遺伝子関連疾患の治療
WO2010148050A2 (en) 2009-06-16 2010-12-23 Curna, Inc. Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
BRPI1015234A2 (pt) 2009-06-22 2018-02-20 Medimmune Llc regiões fc projetadas para conjugação sítio específica.
US8859515B2 (en) 2009-06-24 2014-10-14 Curna, Inc. Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2
EP2446037B1 (de) 2009-06-26 2016-04-20 CuRNA, Inc. Behandlung von krankheiten im zusammenhang mit dem down-syndrom-gen durch hemmung des natürlichen antisense-transkripts zu einem down-syndrom-gen
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
US20120131701A1 (en) 2009-08-05 2012-05-24 Chromocell Corporation Improved plants, microbes, and organisms
CA2769665A1 (en) 2009-08-05 2011-02-10 Opko Curna, Llc Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
CN102482671B (zh) 2009-08-25 2017-12-01 库尔纳公司 通过抑制‘含有iq模体的gtp酶激活蛋白’(iqgap)的天然反义转录物而治疗iqgap相关疾病
US20110059111A1 (en) 2009-09-01 2011-03-10 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Mammalian receptors as targets for antibody and active vaccination therapy against mold infections
CA2772715C (en) 2009-09-02 2019-03-26 Genentech, Inc. Mutant smoothened and methods of using the same
WO2011029823A1 (en) 2009-09-09 2011-03-17 Novartis Ag Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
CA2780741C (en) 2009-10-12 2023-04-04 Smith Holdings, Llc Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
EP2470569A1 (de) 2009-10-13 2012-07-04 Oxford Biotherapeutics Ltd. Antikörper gegen epha10
WO2011050194A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
EP2357239A1 (de) 2009-10-29 2011-08-17 Universität zu Köln Verfahren und Mittel für ein auswählbares Markierungssystem bei Pflanzen
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
WO2011056234A1 (en) 2009-11-06 2011-05-12 Fibrogen, Inc. Treatment for radiation-induced disorders
CA2781669A1 (en) * 2009-11-23 2011-05-26 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
TWI507524B (zh) 2009-11-30 2015-11-11 Genentech Inc 診斷及治療腫瘤之組合物及方法
US9428586B2 (en) 2009-12-01 2016-08-30 Compugen Ltd Heparanase splice variant
AU2010329847A1 (en) 2009-12-11 2012-07-26 Genecode As Methods of facilitating neural cell survival using GDNF family ligand (GFL) mimetics or RET signaling pathway activators
TW201136604A (en) 2009-12-14 2011-11-01 Oncotherapy Science Inc TMEM22 peptides and vaccines including the same
WO2011084455A2 (en) 2009-12-16 2011-07-14 Opko Curna, Llc. Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
WO2011084357A1 (en) 2009-12-17 2011-07-14 Schering Corporation Modulation of pilr to treat immune disorders
MX369004B (es) 2009-12-18 2019-10-24 Novartis Ag Composiciones orgánicas para tratar las enfermedades relacionadas con hsf1.
RU2619185C2 (ru) 2009-12-23 2017-05-12 Курна, Инк. Лечение заболеваний, связанных с разобщающим белком 2 (ucp2), путем ингибирования природного антисмыслового транскрипта к ucp2
KR101891352B1 (ko) 2009-12-23 2018-08-24 큐알엔에이, 인크. 간세포 성장 인자(ｈｇｆ)에 대한 천연 안티센스 전사체의 억제에 의한 ｈｇｆ 관련 질환의 치료
EP2519633B1 (de) 2009-12-29 2017-10-25 CuRNA, Inc. Behandlung von erkrankungen im zusammenhang mit dem nuclear-respirator-faktor 1 (nrf1) mittels hemmung des natürlichen antisense-transkripts gegen nrf1
JP5982288B2 (ja) 2009-12-29 2016-08-31 カッパーアールエヌエー，インコーポレイテッド 腫瘍タンパク質６３（ｐ６３）に対する天然アンチセンス転写物の阻害による腫瘍タンパク質６３関連疾患の治療
NO2521784T3 (de) 2010-01-04 2018-05-05
EP2521785B1 (de) 2010-01-06 2022-03-09 CuRNA, Inc. Inhibition des natürlichen antisense-transkripts des pankreasentwicklungsgens zur verwendung in der behandlung von pankreatischen entwicklungsgenbezogenen krankheiten
ES2664866T3 (es) 2010-01-11 2018-04-23 Curna, Inc. Tratamiento de enfermedades relacionadas con la globulina fijadora de hormonas sexuales (shbg) mediante inhibición del transcrito antisentido natural a shbg
US8883739B2 (en) 2010-01-19 2014-11-11 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for male reproductive disorders
CA2786568A1 (en) 2010-01-25 2011-07-28 Curna, Inc. Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
EA201201113A1 (ru) 2010-02-10 2013-03-29 Новартис Аг Способы и соединения для роста мышц
JP5976548B2 (ja) 2010-02-22 2016-08-23 カッパーアールエヌエー，インコーポレイテッド Ｐｙｃｒ１に対する天然アンチセンス転写物の阻害によるピロリン−５−カルボン酸レダクターゼ１（ｐｙｃｒ１）関連疾患の治療
SG183335A1 (en) 2010-02-23 2012-09-27 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
KR101637138B1 (ko) 2010-02-24 2016-07-06 이뮤노젠 아이엔씨 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도
US8933014B2 (en) 2010-03-11 2015-01-13 Oncotherapy Science, Inc. HJURP peptides and vaccines including the same
AU2011227335B2 (en) 2010-03-17 2014-11-06 Abbott Research B.V. Anti-nerve growth factor (NGF) antibody compositions
EP2371864A1 (de) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoklonale Antikörper zur Krebsbehandlung
EP2550000A4 (de) 2010-03-24 2014-03-26 Advirna Inc Selbstfreisetzende rnai-verbindungen von reduzierter grösse
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
BR112012024565B1 (pt) 2010-03-26 2022-02-08 Trustees Of Dartmouth College Proteína de fusão vista imunossupressora multimérica isolada ou recombinante e composição
TWI538685B (zh) 2010-04-02 2016-06-21 腫瘤療法 科學股份有限公司 Ｅｃｔ２胜肽及含此胜肽之疫苗
WO2011127337A2 (en) 2010-04-09 2011-10-13 Opko Curna Llc Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
BR112012026227A2 (pt) 2010-04-13 2020-08-04 Celldex Therapeutics, Inc. anticorpo monoclonal humano ou humanizado, molécula biespecífica, vetor de expressão, célula transformada, composição, e, usos de um anticorpo
WO2011130716A2 (en) 2010-04-16 2011-10-20 Access Pharmaceuticals, Inc. A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
US8344127B2 (en) 2010-04-23 2013-01-01 Novartis Ag Organic compositions to treat beta-ENaC-related diseases
SI2563920T1 (sl) 2010-04-29 2017-05-31 Ionis Pharmaceuticals, Inc. Modulacija izražanja transtiretina
SG185027A1 (en) 2010-05-03 2012-11-29 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
WO2011139387A1 (en) 2010-05-03 2011-11-10 Opko Curna, Llc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
WO2011140151A1 (en) 2010-05-04 2011-11-10 Dyax Corp. Antibodies against epidermal growth factor receptor (egfr)
AU2011248124B2 (en) 2010-05-05 2016-07-21 The Board Of Trustees Of The University Of Illinois Compounds and methods of treating brain disorders
PE20130206A1 (es) 2010-05-06 2013-02-28 Novartis Ag Anticuerpos multivalentes antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones
EP4234698A3 (de) 2010-05-06 2023-11-08 Novartis AG Zusammensetzungen und verfahren zur verwendung von therapeutischen antikörpern gegen ldl-assoziiertes protein 6 (lrp6)
JP5866106B2 (ja) 2010-05-12 2016-02-17 コロンビア ユニヴァーシティ インスリンを産生し分泌する腸内分泌細胞の製造方法
TWI586356B (zh) 2010-05-14 2017-06-11 可娜公司 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
GB201008720D0 (en) 2010-05-25 2010-07-07 Univ Aberdeen RxLR-leader peptides and protein translocation
RU2585229C2 (ru) 2010-05-26 2016-05-27 Курна, Инк. Лечение заболеваний, связанных с атональным гомологом 1 (атон1), путем ингибирования природного антисмыслового транскрипта гена атон1
US20130209463A1 (en) 2010-06-30 2013-08-15 Compugen Ltd. Polypeptides and uses thereof as a drug for treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders
RU2611190C2 (ru) 2010-07-14 2017-02-21 Курна, Инк. Лечение заболеваний, связанных с геном dlg, путем ингибирования природного антисмыслового транскрипта гена dlg
GB201012420D0 (en) 2010-07-23 2010-09-08 Univ Erasmus Medical Ct Foetal heamoglobin inhibitor
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
MY162825A (en) 2010-08-20 2017-07-31 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
AU2011293437B2 (en) 2010-08-24 2015-09-17 Sgc Pharma, Inc. Salt compound
EP2616100B1 (de) 2010-09-17 2016-08-31 Compugen Ltd. Zusammensetzungen und verfahren zur behandlung von wirkstoffresistentem multiplem myelom
AU2011309689B2 (en) 2010-09-28 2015-01-15 Hadasit Medical Research Services & Development Ltd. Compositions and methods for treatment of hematological malignancies
EP2621954A1 (de) 2010-10-01 2013-08-07 Oxford Biotherapeutics Ltd. Anti-rori-antikörper
WO2012045703A1 (en) 2010-10-05 2012-04-12 Novartis Ag Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders
JP5974012B2 (ja) 2010-10-05 2016-08-23 ジェネンテック， インコーポレイテッド 突然変異体スムースンド及びその使用方法
ES2640755T3 (es) 2010-10-06 2017-11-06 Curna, Inc. Tratamiento de enfermedades relacionadas con la Sialidasa 4 (neu4) mediante inhibición del transcrito antisentido natural al gen neu4
WO2012054723A2 (en) 2010-10-22 2012-04-26 Opko Curna Llc Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
RU2611195C2 (ru) 2010-10-27 2017-02-21 Курна, Инк. Лечение заболеваний, связанных с интерферон- связанным регулятором развития 1 (ifrd1), путем ингибирования природного антисмыслового транскрипта к ifrd1
EP3327125B1 (de) 2010-10-29 2020-08-05 Sirna Therapeutics, Inc. Rna-interferenz-vermittelte inhibition von genexpression unter verwendung kurzer interferierender nukleinsäure (sina)
US20140134181A1 (en) 2010-11-05 2014-05-15 Kenneth E. Lipson Treatment Method For Lung Remodeling Diseases
CA2818824A1 (en) 2010-11-23 2012-05-31 Joseph Collard Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
KR101697396B1 (ko) 2011-02-02 2017-01-17 엑스칼리아드 파마슈티컬즈, 인코포레이티드 결합 조직 성장 인자（ctgf）를 표적으로 하는 안티센스 화합물을 사용하여 켈로이드 또는 비후성 흉터를 치료하는 방법
WO2012109495A1 (en) 2011-02-09 2012-08-16 Metabolic Solutions Development Company, Llc Cellular targets of thiazolidinediones
WO2012119989A2 (en) 2011-03-04 2012-09-13 Oryzon Genomics, S.A. Methods and antibodies for the diagnosis and treatment of cancer
WO2012122313A2 (en) 2011-03-08 2012-09-13 Access Pharmaceuticals, Inc. Targeted nanocarrier systems for delivery of actives across biological membranes
EP2694106B1 (de) 2011-04-01 2017-12-13 ImmunoGen, Inc. Verfahren zur erhöhung der wirksamkeit einer folr1-krebstherapie
WO2012142458A1 (en) 2011-04-13 2012-10-18 Isis Pharmaceuticals, Inc. Antisense modulation of ptp1b expression
EP2697256A1 (de) 2011-04-15 2014-02-19 Compugen Ltd. Polypeptide und polynukleotide sowie ihre verwendung zur behandlung von immunerkrankungen und krebs
ES2653247T3 (es) 2011-06-09 2018-02-06 Curna, Inc. Tratamiento de enfermedades relacionadas con la frataxina (FXN) mediante inhibición del transcrito antisentido natural al gen FXN
CA2839437A1 (en) 2011-06-16 2012-12-20 Isis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
EP2726508B1 (de) 2011-06-28 2017-08-09 Oxford BioTherapeutics Ltd Antikörper gegen adp-ribosyl- cyclase-2
CA2836855C (en) 2011-06-30 2020-07-14 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
ES2810424T3 (es) 2011-06-30 2021-03-08 Genzyme Corp Inhibidores de la activación de células T
PL2726099T3 (pl) 2011-07-01 2018-12-31 Novartis Ag Sposób leczenia zaburzeń metabolicznych
US9238689B2 (en) 2011-07-15 2016-01-19 Morpho Sys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT)
EP2734232B1 (de) 2011-07-19 2017-11-01 Philogen S.p.A. Sequentielle anti-ctla4 und zielgerichtete il-2 therapie
WO2013016714A1 (en) 2011-07-28 2013-01-31 Sea Lane Biotechnologies Sur-binding proteins against erbb3
EP3521432A1 (de) 2011-09-02 2019-08-07 Arrowhead Pharmaceuticals, Inc. Organische zusammensetzungen zur behandlung von hsf1-bedingten erkrankungen
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
CN108410868A (zh) 2011-09-20 2018-08-17 Ionis制药公司 Gcgr表达的反义调节
WO2013043569A1 (en) 2011-09-20 2013-03-28 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
KR20140084232A (ko) 2011-10-25 2014-07-04 아이시스 파마수티컬즈 인코포레이티드 Gccr 발현의 안티센스 조절
EP3296317B1 (de) 2011-10-28 2019-12-11 OncoTherapy Science, Inc. Topk-peptide und impfstoffe damit
KR102151383B1 (ko) 2011-12-05 2020-09-03 노파르티스 아게 표피 성장 인자 수용체 3 (her3)에 대한 항체
EA201491107A1 (ru) 2011-12-05 2014-11-28 Новартис Аг Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен ii her3
CA2858741C (en) 2011-12-07 2018-07-31 Universidade Do Minho Folate-targeted liposomes
ES2710916T3 (es) 2011-12-22 2019-04-29 I2 Pharmaceuticals Inc Proteínas de unión sustitutas
WO2013093809A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
CN104302768A (zh) 2012-01-09 2015-01-21 诺华股份有限公司 治疗β-联蛋白相关疾病的有机组合物
JP2015512616A (ja) 2012-02-01 2015-04-30 コンピュゲン エルティーディー． Ｃ１ｏｒｆ３２抗体およびがんの治療のためのその使用
SI2814829T1 (sl) 2012-02-13 2017-02-28 Bristol-Myers Squibb Company Spojine enediyna, njegovi konjugati in uporaba in postopki
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
CA2867262C (en) 2012-03-15 2021-03-16 Curna, Inc. Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
HUE040256T2 (hu) 2012-03-16 2019-02-28 Merck Patent Gmbh Aminosav lipidek
SG10201610401XA (en) 2012-03-16 2017-01-27 Merck Patent Gmbh Targeting aminoacid lipids
WO2013142796A2 (en) 2012-03-23 2013-09-26 Bristol-Myers Squibb Company Methods of treatments using ctla4 antibodies
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
US9289507B2 (en) 2012-05-17 2016-03-22 Extend Biosciences, Inc. Carriers for improved drug delivery
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
ES2703540T3 (es) 2012-06-04 2019-03-11 Novartis Ag Métodos de marcación específicos del sitio y moléculas producidas de este modo
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
SG11201500938XA (en) 2012-08-31 2015-04-29 Immunogen Inc Diagnostic assays and kits for detection of folate receptor 1
CN109793893B (zh) 2012-09-07 2023-05-26 达特茅斯大学理事会 用于诊断和治疗癌症的vista调节剂
WO2014041179A1 (en) 2012-09-17 2014-03-20 Chemedest Ltd. Treatment of peripheral neuropathy using gfr(alpha)3 type receptor agonists
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
WO2014062697A2 (en) 2012-10-16 2014-04-24 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
DK2722341T3 (en) 2012-10-22 2018-03-12 Fountain Biopharma Inc Interleukin-6 antibodies and their applications
US20150299803A1 (en) 2012-11-05 2015-10-22 Pronai Therapeutics, Inc. Methods of Using Biomarkers for the Treatment of Cancer by Modulation of BCL2 Expression
KR20150082503A (ko) 2012-11-09 2015-07-15 화이자 인코포레이티드 혈소판 유래 성장 인자 b 특이적 항체, 및 그의 조성물 및 용도
PE20151612A1 (es) 2012-12-18 2015-11-19 Novartis Ag Polipeptidos estabilizados del factor de crecimiento tipo insulina
SI2953976T1 (sl) 2013-02-08 2021-08-31 Novartis Ag Specifična mesta z modificiranje protiteles za izdelavo imunokonjugatov
EP2953969B1 (de) 2013-02-08 2019-08-28 Novartis AG Anti-il-17a-antikörper und deren verwendung zur behandlung von autoimmun- und entzündungserkrankungen
WO2014124258A2 (en) 2013-02-08 2014-08-14 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
ES2628156T3 (es) 2013-02-14 2017-08-01 Bristol-Myers Squibb Company Compuestos de tubulisina, métodos para su fabricación y su uso
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
CA2926384A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Low acidic species compositions and methods for producing and using the same
AU2014240431A1 (en) 2013-03-14 2015-08-27 Abbvie Inc. Low acidic species compositions and methods for producing the same using displacement chromatography
EP2970479B1 (de) 2013-03-14 2019-04-24 Novartis AG Antikörper gegen notch 3
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
WO2014150937A1 (en) 2013-03-15 2014-09-25 Novartis Ag Antibody drug conjugates
US10052364B2 (en) 2013-03-15 2018-08-21 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for cognitive disorders
EP3007704B1 (de) 2013-06-13 2021-01-06 Antisense Therapeutics Ltd Kombinationstherapie der akromegalie
EP4001275A1 (de) 2013-06-26 2022-05-25 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH (s)-enantiomer von mepazin als paracaspase (malt1) inhibitor zur behandlung von krebs
TR201820859T4 (tr) 2013-08-14 2019-01-21 Inst Of Genetics And Developmental Biology Bitkilerde tohum ve organ büyüklüğünü modüle etme yöntemleri.
AU2014312086B2 (en) 2013-08-30 2020-03-12 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
US11236338B2 (en) 2013-09-05 2022-02-01 Sarepta Therapeutics, Inc. Antisense-induced exon2 inclusion in acid alpha-glucosidase
EP3045917A2 (de) 2013-09-13 2016-07-20 Sierra Jiménez, Angels Marker für die vorhersage von metastasen eines mammakarzinoms
EP3047023B1 (de) 2013-09-19 2019-09-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Zusammensetzungen und methoden zur inhibierung des jc virus (jcv)
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
US20160271265A1 (en) 2013-10-02 2016-09-22 Novartis Ag Insulin-like growth factor mimetics for use in therapy
RS61620B1 (sr) 2013-10-11 2021-04-29 Oxford Bio Therapeutics Ltd Konjugovana antitela prema ly75 za lečenje kancera
GB201319876D0 (en) 2013-11-11 2013-12-25 Plant Bioscience Ltd Methods of modulating seed and organ size in plants
CN113150144A (zh) 2013-11-13 2021-07-23 辉瑞大药厂 肿瘤坏死因子样配体1a特异性抗体及其组合物和用途
EP3071971B1 (de) 2013-11-19 2019-04-24 Purdue Research Foundation Patientenauswahlverfahren für entzündungen
UY35874A (es) 2013-12-12 2015-07-31 Novartis Ag Un proceso para la preparación de una composición de proteínas pegiladas
KR102534681B1 (ko) 2013-12-24 2023-05-18 잔센파마슈티카엔.브이. 항-vista 항체 및 단편
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
AU2015214264B2 (en) 2014-02-04 2018-12-20 Curis, Inc. Mutant Smoothened and methods of using the same
WO2015138615A2 (en) 2014-03-12 2015-09-17 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
WO2015171918A2 (en) 2014-05-07 2015-11-12 Louisiana State University And Agricultural And Mechanical College Compositions and uses for treatment thereof
GB201408623D0 (en) 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
EA037006B1 (ru) 2014-06-06 2021-01-26 Бристол-Майерс Сквибб Компани Антитела к индуцируемому глюкокортикоидами рецептору фактора некроза опухолей (gitr) и их применения
WO2015191881A2 (en) 2014-06-11 2015-12-17 Green Kathy A Use of vista agonists and antagonists to suppress or enhance humoral immunity
US20170291939A1 (en) 2014-06-25 2017-10-12 Novartis Ag Antibodies specific for il-17a fused to hyaluronan binding peptide tags
US10487314B2 (en) 2014-06-26 2019-11-26 The Trustees Of Columbia University In The City Of New York Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
US20170226552A1 (en) 2014-07-03 2017-08-10 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
US20160185848A1 (en) 2014-07-09 2016-06-30 Abbvie Inc. Methods for modulating the glycosylation profile of recombinant proteins using sugars
EP3539990B1 (de) 2014-07-16 2021-09-08 Dana-Farber Cancer Institute, Inc. Her3-inhibition bei serösem low-grade ovarialkarzinom
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
US10457721B2 (en) 2014-08-11 2019-10-29 University Of Massachusetts Anti-OSPA antibodies and methods of use
US9982045B2 (en) 2014-08-12 2018-05-29 Novartis Ag Anti-CDH6 antibody drug conjugates
EP3185885B1 (de) 2014-08-26 2020-08-19 Compugen Ltd. Polypeptide und verwendungen davon als arzneimittel zur behandlung von autoimmunerkrankungen
WO2016033424A1 (en) 2014-08-29 2016-03-03 Genzyme Corporation Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
EP2993174A1 (de) 2014-09-08 2016-03-09 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Pyrazolopyridinderivate und deren Verwendung in der Therapie
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US10647687B2 (en) 2014-11-10 2020-05-12 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death
JOP20200092A1 (ar) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
SG11201703464UA (en) 2014-11-14 2017-05-30 Novartis Ag Antibody drug conjugates
JP7175608B2 (ja) 2014-11-19 2022-11-21 ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 加齢に伴うフレイルのための治療としてのオステオカルシン
KR20230125855A (ko) 2014-11-21 2023-08-29 브리스톨-마이어스 스큅 컴퍼니 Cd73에 대항한 항체 및 그의 용도
PT3221346T (pt) 2014-11-21 2020-10-23 Bristol Myers Squibb Co Anticorpos compreendendo regiões constantes de cadeia pesada modificadas
EP3224277B1 (de) 2014-11-25 2020-08-26 Bristol-Myers Squibb Company Neuartige pd-l1-bindende polypeptide zur bildgebung
CN107207379B (zh) 2014-11-25 2021-08-10 百时美施贵宝公司 用于生物制品的18f-放射性标记的方法和组合物
EP3227341A1 (de) 2014-12-02 2017-10-11 CeMM - Forschungszentrum für Molekulare Medizin GmbH Anti-mutante calreticulin-antikörper und deren verwendung bei der diagnose und therapie von myeloiden malignomen
AU2015357463B2 (en) 2014-12-05 2021-10-07 Immunext, Inc. Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators
US10689459B2 (en) 2014-12-12 2020-06-23 Novartis Ag Treatment of breast cancer brain metastases
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
ES2881346T3 (es) 2014-12-19 2021-11-29 Regenesance B V Anticuerpos que se unen a C6 humano y usos de los mismos
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
MY187045A (en) 2014-12-23 2021-08-27 Bristol Myers Squibb Co Antibodies to tigit
AU2016206808A1 (en) 2015-01-14 2017-08-31 Bristol-Myers Squibb Company Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using
TW201632202A (zh) 2015-01-30 2016-09-16 諾華公司 乳癌之治療
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
WO2016144773A1 (en) 2015-03-06 2016-09-15 Abbvie Inc. Arabinosylated glycoproteins
EP3268037B1 (de) 2015-03-09 2022-08-31 Celldex Therapeutics, Inc. Cd27 agonists
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
RU2017130313A (ru) 2015-04-10 2019-05-13 Гельмгольц Центрум Мюнхен - Дойчес Форшунгсцентрум Фюр Гезундхайт Унд Умвельт (Гмбх) Производные пирона для применения в терапии
EP4014985A1 (de) 2015-05-01 2022-06-22 Allysta Pharmaceuticals, Inc. Adiponectin-peptidomimetika zur behandlung von augenerkrankungen
EP3447075B1 (de) 2015-05-15 2023-08-09 The General Hospital Corporation Antagonistische anti-tumor-nekrosefaktorrezeptorsuperfamilienantikörper
EP3297676A2 (de) 2015-05-22 2018-03-28 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Kombination aus trpm8-agonist und nachr-agonist zur behandlung von obesitas und verwandten erkrankungen sowie zur gewichtsreduzierung
US20180161272A1 (en) * 2015-05-26 2018-06-14 The General Hospital Corporation Liposomal nanoconstructs and methods of making and using the same
CN108137687B (zh) 2015-05-29 2021-10-29 百时美施贵宝公司 抗ox40抗体及其用途
EP3302497A4 (de) 2015-06-01 2019-01-16 Sarepta Therapeutics, Inc. Antisense-induszierte exonexklusion in typ-vii-kollagen
WO2016203432A1 (en) 2015-06-17 2016-12-22 Novartis Ag Antibody drug conjugates
BR112017027870A2 (pt) 2015-06-24 2018-08-28 Janssen Pharmaceutica Nv anticorpos e fragmentos anti-vista
KR20180021833A (ko) 2015-06-29 2018-03-05 더 락커펠러 유니버시티 증진된 효능제 활성을 갖는 cd40에 대한 항체
CA2991980A1 (en) 2015-07-13 2017-01-19 Compugen Ltd. Hide1 compositions and methods
CA3025896A1 (en) 2015-07-23 2017-01-26 The Regents Of The University Of California Antibodies to coagulation factor xia and uses thereof
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
MA42844A (fr) 2015-09-17 2018-07-25 Immunogen Inc Combinaisons thérapeutiques comprenant des immunoconjugués anti-folr1
WO2017058881A1 (en) 2015-09-28 2017-04-06 The Trustees Of Columbia University In The City Of New York Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
RU2638457C2 (ru) 2015-09-28 2017-12-13 Общество С Ограниченной Ответственностью "Онкомакс" Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
EP3355914B1 (de) 2015-09-29 2024-03-06 The General Hospital Corporation Eine bcg-haltige zusammensetzung zur cholesterolsenkung.
MA45819A (fr) 2015-10-09 2018-08-15 Sarepta Therapeutics Inc Compositions et méthodes pour traiter la dystrophie musculaire de duchenne et troubles associés
EP3365369A1 (de) 2015-10-23 2018-08-29 Pfizer Inc Anti-il-2-antikörper sowie zusammensetzungen und verwendungen davon
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
AU2016349954B2 (en) 2015-11-05 2022-08-25 Antisense Therapeutics Ltd Mobilizing leukemia cells
CN106699889A (zh) 2015-11-18 2017-05-24 礼进生物医药科技（上海）有限公司 抗pd-1抗体及其治疗用途
WO2017087678A2 (en) 2015-11-19 2017-05-26 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
US10946106B2 (en) 2015-11-30 2021-03-16 The Regents Of The University Of California Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
EP3383903A1 (de) 2015-11-30 2018-10-10 Bristol-Myers Squibb Company Humane ip-10-antikörper und deren verwendung
US20210198368A1 (en) 2016-01-21 2021-07-01 Novartis Ag Multispecific molecules targeting cll-1
CN109071625A (zh) 2016-02-04 2018-12-21 柯瑞斯公司 平滑化突变体和其使用方法
BR112018016461A2 (pt) 2016-02-12 2019-10-01 Janssen Pharmaceutica Nv anticorpos e fragmentos anti-vista, usos dos mesmos e métodos de identificação dos mesmos
CN108699142A (zh) 2016-02-17 2018-10-23 诺华股份有限公司 TGFβ2抗体
KR20230038311A (ko) 2016-03-04 2023-03-17 브리스톨-마이어스 스큅 컴퍼니 항-cd73 항체와의 조합 요법
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
MX2018010672A (es) 2016-03-04 2019-05-27 Univ Rockefeller Anticuerpos para cumulo de diferenciación 40 (cd40) con actividad agonista mejorada.
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
CR20180537A (es) 2016-04-15 2019-03-04 Immunext Inc Anticuerpos vista antihumanos y su uso
EP3445405A4 (de) 2016-04-18 2019-12-18 Sarepta Therapeutics, Inc. Antisense-oligomere und verfahren zur verwendung davon zur behandlung von erkrankungen in zusammenhang mit dem saure-alpha-glucosidase-gen
CA3021328A1 (en) 2016-04-18 2017-10-26 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
BR112018069417A2 (pt) 2016-04-22 2019-01-22 Biontech Rna Pharmaceuticals Gmbh método para fornecer rna fita simples e ssrna
WO2017201111A1 (en) 2016-05-19 2017-11-23 Bristol-Myers Squibb Company Pet-imaging immunomodulators
KR102397783B1 (ko) 2016-06-01 2022-05-12 브리스톨-마이어스 스큅 컴퍼니 Pd-l1 결합 폴리펩티드에 의한 pet 영상화
WO2017210335A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Imaging methods using 18f-radiolabeled biologics
US20180002417A1 (en) 2016-06-15 2018-01-04 Celimmune Llc Methods and Compositions for the Treatment of Celiac Disease, Non-Celiac Gluten Sensitivity, and Refractory Celiac Disease
EP3260542A1 (de) 2016-06-20 2017-12-27 Algentech Proteinproduktion in pflanzenzellen
US10077306B2 (en) 2016-07-14 2018-09-18 Bristol-Myers Squibb Company Antibodies against TIM3 and uses thereof
WO2018035391A1 (en) 2016-08-19 2018-02-22 Bristol-Myers Squibb Company Seco-cyclopropapyrroloindole compounds, antibody-drug conjugates thereof, and methods of making and use
WO2018044970A1 (en) 2016-08-31 2018-03-08 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
EP3305781A1 (de) 2016-10-07 2018-04-11 Deutsches Krebsforschungszentrum Chemische substanzen welche die enzymatische aktivität der humanen kallikrein-related peptidase 6 (klk6) hemmen.
JP2020500007A (ja) 2016-10-13 2020-01-09 マサチューセッツ インスティテュート オブ テクノロジー ジカウイルスエンベロープタンパク質に結合する抗体およびその使用
US10538556B2 (en) 2016-11-07 2020-01-21 Colorado State University Research Foundation Anti-HIV peptides
KR102526034B1 (ko) 2016-11-07 2023-04-25 브리스톨-마이어스 스큅 컴퍼니 면역조정제
EP3538153A4 (de) 2016-11-11 2020-06-24 The Regents of the University of California Anti-cd46-antikörper und verfahren zur verwendung
PT3565828T (pt) 2017-01-05 2022-02-08 Kahr Medical Ltd Proteína de fusão sirp1 alfa-41bbl e seus métodos de utilização
JP2020505009A (ja) 2017-01-05 2020-02-20 カール メディカル リミテッド Ｐｄ１−４１ｂｂｌ融合タンパク質およびその使用方法
CN110312736B (zh) 2017-01-23 2023-05-09 苏州康宁杰瑞生物科技有限公司 Pd-l1结合多肽或化合物
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
EA201991720A1 (ru) 2017-02-17 2020-01-20 Бристол-Маерс Сквибб Компани Антитела к альфа-синуклеину и их применения
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
US10994025B2 (en) 2017-05-12 2021-05-04 Massachusetts Institute Of Technology Argonaute protein-double stranded RNA complexes and uses related thereto
US11168129B2 (en) 2017-05-15 2021-11-09 University Of Rochester Broadly neutralizing anti-influenza human monoclonal antibody and uses thereof
US20200299400A1 (en) 2017-05-25 2020-09-24 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
CA3066077A1 (en) 2017-06-07 2018-12-13 Adrx, Inc. Tau aggregation inhibitors
US20210147571A1 (en) 2017-06-23 2021-05-20 Suzhou Bojuhua Biomedical Technology Co. Ltd Monoclonal antibody targeting human tumor stem cells and use thereof
KR20200020858A (ko) 2017-06-23 2020-02-26 브리스톨-마이어스 스큅 컴퍼니 Pd-1의 길항제로서 작용하는 면역조정제
CA3073062A1 (en) 2017-08-18 2019-02-21 Adrx, Inc. Tau aggregation peptide inhibitors
AU2018325842A1 (en) 2017-08-28 2020-04-16 Shanghai Yile Biotechnology Co, . Ltd. Polypeptide and antibody bound to polypeptide
CN111051332A (zh) 2017-10-03 2020-04-21 百时美施贵宝公司 免疫调节剂
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. ANTI-LAP ANTIBODIES AND USES THEREOF
US11555189B2 (en) 2017-10-18 2023-01-17 Sarepta Therapeutics, Inc. Antisense oligomer compounds
CN117106096A (zh) 2017-10-26 2023-11-24 盛禾(中国)生物制药有限公司 新的重组融合蛋白及其制备和用途
US11603410B2 (en) 2017-11-01 2023-03-14 Bristol-Myers Squibb Company Immunostimulatory agonistic antibodies for use in treating cancer
BR112020008438A2 (pt) 2017-11-02 2020-10-20 Oxford Biotherapeutics Ltd anticorpos e métodos de uso
EP3717510A2 (de) 2017-12-01 2020-10-07 Novartis AG Polyomavirus-neutralisierende antikörper
JP7391839B2 (ja) 2017-12-01 2023-12-05 ファイザー・インク 抗ｃｘｃｒ５抗体、その組成物及びその使用
PL3710484T3 (pl) 2017-12-20 2024-03-25 Harbour Biomed (Shanghai) Co., Ltd Przeciwciała wiążące ctla-4 i ich zastosowania
EP3728200A1 (de) 2017-12-21 2020-10-28 Gliapharm SA Zusammensetzungen und verfahren zur behandlung von neurologischen störungen einschliesslich motoneuronenerkrankungen
WO2019123378A1 (en) 2017-12-21 2019-06-27 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising a dementia
CN111788227A (zh) 2017-12-27 2020-10-16 百时美施贵宝公司 抗cd40抗体及其用途
WO2019140229A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
US20210363172A1 (en) 2018-03-15 2021-11-25 Biontech Rna Pharmaceuticals Gmbh 5'-cap-trinucleotide- or higher oligonucleotide compounds and their use in stabilizing rna, expressing proteins in therapy
KR20200135830A (ko) 2018-03-23 2020-12-03 브리스톨-마이어스 스큅 컴퍼니 Mica 및/또는 micb에 대한 항체 및 그의 용도
EP3777889A4 (de) 2018-03-26 2022-01-26 Shanghai Yile Biotechnology Co., Ltd. Verwendung von probdnf-regulator in b-zell-verwandten krankheiten
WO2019185129A1 (en) 2018-03-27 2019-10-03 The University Court Of The University Of Glasgow Bacterial pathogen derived resistance in plants
KR20200136465A (ko) 2018-03-29 2020-12-07 화이자 인코포레이티드 Lfa3 변이체 및 그의 조성물 및 용도
CN111936520A (zh) 2018-04-02 2020-11-13 百时美施贵宝公司 抗trem-1抗体及其用途
JP2021520781A (ja) 2018-04-06 2021-08-26 チルドレンズ メディカル センター コーポレーションＣｈｉｌｄｒｅｎ’Ｓ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ Ｃｏｒｐｏｒａｔｉｏｎ 体細胞リプログラミングおよびインプリンティングのモジュレートのための組成物および方法
WO2019200256A1 (en) 2018-04-12 2019-10-17 Bristol-Myers Squibb Company Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
US20210198374A1 (en) 2018-04-17 2021-07-01 Celldex Therapeutics, Inc. Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
US20210179602A1 (en) 2018-04-20 2021-06-17 Iomx Therapeutics Ag A 5-thiazolecarboxamide kinase inhibitor and uses thereof
JP7402541B2 (ja) 2018-05-03 2023-12-21 ユニバーシティ オブ ロチェスター 抗インフルエンザノイラミニダーゼモノクローナル抗体およびその使用
CN112165974A (zh) 2018-05-31 2021-01-01 诺华股份有限公司 乙型肝炎抗体
PE20210320A1 (es) 2018-06-01 2021-02-16 Novartis Ag Moleculas de union contra bcma y usos de las mismas
GB201809746D0 (en) 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
EP3826659A4 (de) 2018-07-10 2022-06-29 Rush University Medical Center Verwendung von immunmodulatoren zur infektionskontrolle und förderung der heilung bei normalen und diabetischen wunden
JP2021529547A (ja) 2018-07-11 2021-11-04 カール メディカル リミテッド ＳＩＲＰα−４−１ＢＢＬバリアント融合タンパク質及びその使用方法
EP3833690B1 (de) 2018-08-08 2024-03-27 ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Gegen cd47 und her2 gerichtetes, rekombinantes bifunktionales protein
JP2021533767A (ja) 2018-08-13 2021-12-09 アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. Ｂ型肝炎ウイルス（ＨＢＶ）ｄｓＲＮＡ物質組成物およびその使用方法
JP2022508015A (ja) 2018-09-07 2022-01-19 ファイザー・インク 抗αｖβ８抗体、組成物及びその使用
WO2020053742A2 (en) 2018-09-10 2020-03-19 Novartis Ag Anti-hla-hbv peptide antibodies
EP3863722A2 (de) 2018-10-10 2021-08-18 Tilos Theapeutics, Inc. Anti-lap-antikörper und verwendungen davon
EP3643713A1 (de) 2018-10-23 2020-04-29 iOmx Therapeutics AG Heterocyclische kinasehemmer und verwendungen davon
EP3870572A1 (de) 2018-10-23 2021-09-01 Myelopro Diagnostics and Research GmbH Verbindungen gegen mutiertes calreticulin
WO2020097627A1 (en) 2018-11-09 2020-05-14 University Of Massachusetts Anti-cfae antibodies and methods of use
SG11202104969RA (en) 2018-11-16 2021-06-29 Bristol Myers Squibb Co Anti-nkg2a antibodies and uses thereof
CN113348177A (zh) 2018-11-28 2021-09-03 百时美施贵宝公司 包含经修饰的重链恒定区的抗体
WO2020128863A1 (en) 2018-12-19 2020-06-25 Novartis Ag Anti-tnf-alpha antibodies
CA3122526C (en) 2018-12-21 2023-01-03 Ose Immunotherapeutics Humanized anti-human-pd-1 antibody
CN113573782A (zh) 2018-12-21 2021-10-29 Ose免疫疗法公司 针对人pd-1的双功能分子
EP3898676A1 (de) 2018-12-21 2021-10-27 OSE Immunotherapeutics Bifunktionales anti-pd1-/sirpa-molekül
CN113195541A (zh) 2018-12-21 2021-07-30 诺华股份有限公司 针对pmel17的抗体及其缀合物
JP2022514702A (ja) 2018-12-21 2022-02-14 オーエスイー・イミュノセラピューティクス 二機能性抗ｐｄ－１／ｉｌ－７分子
WO2020132378A2 (en) 2018-12-22 2020-06-25 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising depression
CN109762067B (zh) 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
JP7393810B2 (ja) 2019-03-08 2023-12-07 アブティス・カンパニー・リミテッド 部位特異的抗体コンジュゲーション及びその具体例としての抗体－薬物コンジュゲート
EP3947458A1 (de) 2019-04-03 2022-02-09 Genzyme Corporation Anti-alpha-beta-tcr bindende polypeptide mit reduzierter fragmentierung
JP2022533215A (ja) 2019-05-20 2022-07-21 ノバルティス アーゲー 親水性基を含むリンカーを有する抗体薬剤コンジュゲート
WO2020237081A1 (en) 2019-05-21 2020-11-26 Bristol-Myers Squibb Company Immunomodulators
WO2021001653A1 (en) 2019-07-03 2021-01-07 Oxford Biotherapeutics Ltd Antibodies and methods of use
EP3997114A1 (de) 2019-07-11 2022-05-18 KAHR Medical Ltd. Heterodimere und verfahren zur verwendung davon
WO2021011681A1 (en) 2019-07-15 2021-01-21 Bristol-Myers Squibb Company Antibodies against human trem-1 and uses thereof
US20220372139A1 (en) 2019-07-15 2022-11-24 Bristol-Myers Squibb Company Anti-trem-1 antibodies and uses thereof
CN114555627A (zh) 2019-10-30 2022-05-27 百时美施贵宝公司 免疫调节剂
JP2023503050A (ja) 2019-11-19 2023-01-26 ブリストル－マイヤーズ スクイブ カンパニー 免疫モジュレーター
KR20220122752A (ko) 2020-01-06 2022-09-02 브리스톨-마이어스 스큅 컴퍼니 면역조정제
JP2023510736A (ja) 2020-01-06 2023-03-15 ブリストル－マイヤーズ スクイブ カンパニー 癌および感染症を治療するためのｐｄ－ｌ１阻害剤および免疫調節剤としての大環状ペプチド
AU2021228061A1 (en) 2020-02-27 2022-10-13 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Antibodies binding IL4R and uses thereof
EP4110407A1 (de) 2020-02-28 2023-01-04 Bristol-Myers Squibb Company Radioaktiv markierte fibronectinbasierte gerüste und antikörper sowie therapeutische verwendungen davon
WO2021183428A1 (en) 2020-03-09 2021-09-16 Bristol-Myers Squibb Company Antibodies to cd40 with enhanced agonist activity
WO2021188480A1 (en) 2020-03-16 2021-09-23 Bristol-Myers Squibb Company Immunomodulators
US20230151059A1 (en) 2020-03-30 2023-05-18 Bristol-Myers Squibb Company Immunomodulators
EP4126934A1 (de) 2020-04-01 2023-02-08 University of Rochester Monoklonale antikörper gegen das hämagglutinin (ha) und die neuraminidase (na) von influenza-h3n2-viren
US20230272056A1 (en) 2020-04-09 2023-08-31 Merck Sharp & Dohme Llc Affinity matured anti-lap antibodies and uses thereof
EP3901151A1 (de) 2020-04-21 2021-10-27 iOmx Therapeutics AG Halogenierte heteroaryl- und andere heterocyclische kinaseinhibitoren und verwendungen davon
US20230192701A1 (en) 2020-04-28 2023-06-22 Iomx Therapeutics Ag Bicyclic kinase inhibitors and uses thereof
TW202216757A (zh) 2020-04-28 2022-05-01 美國洛克菲勒大學 中和性抗ｓａｒｓ－ｃｏｖ－２抗體及其使用方法
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
CN115461363A (zh) 2020-05-01 2022-12-09 诺华股份有限公司 免疫球蛋白变体
US20230242647A1 (en) 2020-05-01 2023-08-03 Novartis Ag Engineered immunoglobulins
WO2021226460A1 (en) 2020-05-08 2021-11-11 Bristol-Myers Squibb Company Immunomodulators
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
US20230277524A1 (en) 2020-05-22 2023-09-07 Trailhead Biosystems Inc. Combination therapy for treatment of viral infections
IL300528A (en) 2020-08-07 2023-04-01 Fortis Therapeutics Inc Immune conjugates targeting cd46 and methods of using them
IL301158A (en) 2020-09-09 2023-05-01 Social Profit Network Methods and preparations for delivering biotin to mitochondria
EP4221841A1 (de) 2020-10-02 2023-08-09 Bristol-Myers Squibb Company Makrocyclische peptidboronat-immunmodulatoren
US20230374073A1 (en) 2020-10-08 2023-11-23 Bristol-Myers Squibb Company Dimeric milla immunomodulators
JP2023545076A (ja) 2020-10-09 2023-10-26 ブリストル－マイヤーズ スクイブ カンパニー 免疫調節剤
WO2022098870A1 (en) 2020-11-04 2022-05-12 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies
WO2022097060A1 (en) 2020-11-06 2022-05-12 Novartis Ag Cd19 binding molecules and uses thereof
IL302412A (en) 2020-11-06 2023-06-01 Novartis Ag Anti-CD19 and B-cell targeting agent combination therapy for the treatment of B-cell malignancies
EP4240765A2 (de) 2020-11-06 2023-09-13 Novartis AG Antikörper-fc-varianten
JP2023547947A (ja) 2020-11-11 2023-11-14 ビオンテック・ソシエタス・エウロパエア プログラム細胞死－１タンパク質に対するモノクローナル抗体および医薬におけるその使用
CN114685669A (zh) 2020-12-30 2022-07-01 和铂医药(苏州)有限公司 结合trop2的抗体及其用途
WO2022155324A1 (en) 2021-01-15 2022-07-21 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies
JP2024512074A (ja) 2021-03-24 2024-03-18 ブリストル－マイヤーズ スクイブ カンパニー 免疫調節剤
BR112023020303A2 (pt) 2021-04-09 2023-11-14 Celldex Therapeutics Inc Anticorpos contra ilt4, anticorpo anti-ilt4/pd-l1 bispecífico e seus usos
KR20230169230A (ko) 2021-04-12 2023-12-15 브리스톨-마이어스 스큅 컴퍼니 시클릭 펩티드 면역조정제
CA3216880A1 (en) 2021-04-16 2022-10-20 Novartis Ag Antibody drug conjugates and methods for making thereof
EP4326873A1 (de) 2021-04-22 2024-02-28 Dana-Farber Cancer Institute, Inc. Zusammensetzungen und verfahren zur behandlung von krebs
WO2022235867A2 (en) 2021-05-06 2022-11-10 The Rockefeller University Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
CA3219316A1 (en) 2021-05-26 2022-12-01 Christian Rohlff Pharmaceutical combination comprising an anti-cd205 antibody and an immune checkpoint inhibitor
KR20240019236A (ko) 2021-06-09 2024-02-14 브리스톨-마이어스 스큅 컴퍼니 시클릭 펩티드 면역조정제
CA3217100A1 (en) 2021-06-09 2022-12-15 Gerald BURGSTALLER Novel anti-fibrotic drugs
WO2023288213A1 (en) 2021-07-12 2023-01-19 Bristol-Myers Squibb Company Macrocyclic immunomodulators
KR20240035843A (ko) 2021-07-19 2024-03-18 브리스톨-마이어스 스큅 컴퍼니 마크로시클릭 면역조정제
CN113773401B (zh) 2021-09-15 2023-06-20 宜明昂科生物医药技术（上海）股份有限公司 靶向cd47和pd-l1的重组融合蛋白及其制备和用途
CN113956363B (zh) 2021-10-13 2023-03-31 宜明昂科生物医药技术（上海）股份有限公司 靶向cd47和cd24的重组融合蛋白及其制备和用途
WO2023069994A1 (en) 2021-10-20 2023-04-27 Bristol-Myers Squibb Company Immunomodulators
WO2023073599A1 (en) 2021-10-28 2023-05-04 Novartis Ag Engineered fc variants
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
WO2023089314A1 (en) 2021-11-18 2023-05-25 Oxford Biotherapeutics Limited Pharmaceutical combinations
WO2023102507A1 (en) 2021-12-03 2023-06-08 Bristol-Myers Squibb Company Macrocyclic immunomodulators
WO2023147399A1 (en) 2022-01-27 2023-08-03 The Rockefeller University Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
WO2023192873A1 (en) 2022-03-28 2023-10-05 Bristol-Myers Squibb Company Macrocyclic immunomodulators
EP4257132A1 (de) 2022-04-08 2023-10-11 iOmx Therapeutics AG Sik3-inhibitoren zum behandeln von krankheiten, die gegen death-rezeptor -signaltransduktion resistent sind
EP4257609A1 (de) 2022-04-08 2023-10-11 iOmx Therapeutics AG Kombinationstherapien basierend auf pd-1-inhibitoren und sik3-inhibitoren
US20230357381A1 (en) 2022-04-26 2023-11-09 Novartis Ag Multispecific antibodies targeting il-13 and il-18
WO2023217987A1 (en) 2022-05-12 2023-11-16 BioNTech SE Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
WO2023225661A1 (en) 2022-05-20 2023-11-23 Bristol-Myers Squibb Company Macrocyclic immunomodulators
WO2024059472A1 (en) 2022-09-12 2024-03-21 Bristol-Myers Squibb Company Macrocyclic immunomodulators
US20240101691A1 (en) 2022-09-21 2024-03-28 Sanofi Biotechnology Humanized anti-il-1r3 antibody and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136159A (en) * 1977-02-28 1979-01-23 New England Nuclear Corporation Radioassay of folates
JPS57186492A (en) * 1981-04-17 1982-11-16 Kyowa Hakko Kogyo Co Ltd Transformation of bacterium
NZ217821A (en) * 1985-10-10 1989-07-27 Biotech Australia Pty Ltd Oral delivery system; complex of active agent and vitamin b12 or analogue thereof
EP0273085A1 (de) * 1986-12-29 1988-07-06 IntraCel Corporation Verfahren zur Einführung fremder Nukleinsäuren in eukaryotische Zellen
US5135736A (en) * 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules

Also Published As

Publication number Publication date
EP0466816B1 (de) 1997-11-26
ES2113346T3 (es) 1998-05-01
JP3232347B2 (ja) 2001-11-26
PT93646A (pt) 1990-11-20
EP0466816A1 (de) 1992-01-22
IE901201A1 (en) 1991-10-09
IL93983A (en) 1997-02-18
DE69031763D1 (de) 1998-01-08
US5108921A (en) 1992-04-28
CA2013582A1 (en) 1990-10-03
WO1990012096A1 (en) 1990-10-18
US5820847A (en) 1998-10-13
DK0466816T3 (da) 1998-08-10
US5416016A (en) 1995-05-16
EP0466816A4 (en) 1992-05-20
IL93983A0 (en) 1991-01-31
AU5437590A (en) 1990-11-05
ATE160583T1 (de) 1997-12-15
IE81171B1 (en) 2000-05-31
CA2013580A1 (en) 1990-10-03
US5635382A (en) 1997-06-03
JPH05502787A (ja) 1993-05-20
CA2013582C (en) 2007-06-19

Similar Documents

Publication Publication Date Title
DE69031763T2 (de) Steigerungsverfahren der transmembranförderung von exogenen molekülen
IT8819693A0 (it) Apparecchio atto ad operare, in modo pressoche' istantaneo, la distruzione completa dell'ago di siringhe per iniezione, subito dopo il loro impiego.
DE3485649D1 (de) Verfahren zur herstellung von antikoerperzusammensetzungen von therapeutischen mitteln mit verlaengerter serumhalbwertzeit.
FI99086C (fi) Ultraäänivarjoaineita, menetelmä niiden valmistamiseksi ja niiden käyttö diagnostisina aineina
DE69519670D1 (de) Mikropartikel mit abgabesystem
MY103850A (en) Phenol substituted gem-diphosphonate derivatives, process for their preparation and pharmaceutical compositions containing them.
IT1207992B (it) Derivati glicosilati dell'insulina.
ES8600263A1 (es) Un compuesto.
SE8600632D0 (sv) Novel pharmaceutical composition
ATE70453T1 (de) Verwendung von interleukin-1-proteinen gegen arthritis.
DE68900029D1 (de) Pyrazolderivate, verfahren zu ihrer herstellung und diese derivate als aktive komponente enthaltende insektizide, mitizide und fungizide zusammensetzungen.
KR840006492A (ko) 플라티늄-디아민 착화물의 제조 방법
ATE27451T1 (de) Acyl-chinolinonderivate, verfahren zu ihrer herstellung, diese enthaltende pharmazeutische praeparate und ihre verwendung.
DE69011645T2 (de) Cycloheptenopyridinderivate, Verfahren zu ihrer Herstellung und diese enthaltende Antiulkusmitteln.
DE59000267D1 (de) Verfahren zur herstellung eines komplexierten arzneimittels.
TR199801659T2 (xx) Yeni triazolopurinler, haz�rlama y�ntemi, ila� olarak kullan�m�.
KR950700684A (ko) 시클릭 항-종양 촉진제 화합물, 그의 조성물, 제조 방법 및 용도(Cyclic Anti-Tumor Promoter Compounds, Compositions and Methods for Production and Use)
ES466371A1 (es) Procedimiento para la preparacion de derivados de acilamino (alcohil)-benceno.
ES8406468A1 (es) Procedimiento para la obtencion de derivados de terc.-butanol sustituidos
ES8403463A1 (es) "un procedimiento para la preparacion de un compuesto de imidazol".
GB1514049A (en) Cross-linked orgotein
DE68906049D1 (de) Benzocyclohexan- und benzocycloheptan-derivate und deren salze, verfahren und zwischenprodukte zu deren herstellung, deren verwendung als heilmittel und diese enthaltende zusammensetzungen.
DE58902684D1 (de) Verfahren zur herstellung von cyclischen n,n'-dimethylharnstoffen.
DE3772965D1 (de) Imidazol-derivate mit therapeutischer aktivitaet, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen.
ATE105570T1 (de) Modifizierte menschliche anti-rh(d)-antikoerper.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee